Functional immunological parameters associated with long-term survival of patients with metastatic melanoma by Zelba, Henning
Functional immunological parameters associated 
with long-term survival of patients with metastatic 
melanoma 
 
 
 
 
 
 
 
 
Dissertation 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Eberhard Karls Universität Tübingen 
zur Erlangung des Grades eines  
Doktors der Naturwissenschaften  
(Dr. rer. nat.) 
 
 
 
 
 
 
vorgelegt von 
Henning Zelba 
aus Leonberg 
  
 
 
 
Tübingen 
2013 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der 
Eberhard Karls Universität Tübingen. 
 
 
Tag der mündlichen Qualifikation:  16.04.2013 
Dekan: Prof. Dr. Wolfgang Rosenstiel 
1. Berichterstatter: Prof. Dr. Graham Pawelec 
2. Berichterstatter: Prof. Dr. Hans-Georg Rammensee 
 
 III 
 
Table of contents: 
Manuscripts embedded in this thesis      01 
Contribution of author      02 
Introduction      03 
Tumor-specific T cells      05 
Tumour escape mechanisms      06 
Aims of the thesis      08 
Results overview and discussion        09 
Intratumoural treatment with Interleukin-2      09 
Functional Specific T Cells in Stage IV Melanoma     10 
Phenotype and Function of the antigen-specific T cell    11 
Concluding remarks         13 
Manuscripts           14 
References           52 
Zusammenfassung          56 
Lebenslauf           58
     
 
 
  
      
 
 
  - 1 - 
 
Manuscripts embedded in this thesis: 
 
Manuscript 1: Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny 
P, Zelba H, et al. High response rate after intratumoral treatment 
with interleukin-2: results from a phase 2 study in 51 patients with 
metastasized melanoma. Cancer. 2010; 4139-46 
 
Manuscript 2: Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler 
TK, Di Giacomo AM, et al. Functional T cells targeting NY-ESO-1 
or Melan-A are predictive for survival of patients with distant 
melanoma metastasis. J Clin Oncol. 2012; 1835-41.  
 
Manuscript 3: Zelba H, Weide B, Derhovanessian E, Pflugfelder A, Eigentler 
TK, et al. Phenotypic and Functional analysis of Melan-A and 
NY-ESO-1-reactive T cells and their influence on survival of late-
stage melanoma patients in preparation 
  
  
      
 
 
  - 2 - 
 
Contribution of author 
 
Manuscript 1:  Collection and assembly of immunological data  Data analysis  Final approval of manuscript 
 
Manuscript 2: 
  Conception and design  Collection and assembly of immunological data   Data analysis and interpretation  Manuscript writing  Final approval of manuscript 
 
Manuscript 3: 
 Conception and design  Collection and assembly of immunological data   Data analysis and interpretation  Manuscript writing  Final approval of manuscript 
  
      
 
 
  - 3 - 
 
Introduction 
 
Melanoma, the malignant tumour of the melanocytes, is one of the most rapidly 
increasing types of cancer worldwide (Ferlay 2007; Ferlay 2010). If detected at an 
early stage (stage I and II; see Figure 1.), surgical removal of visible tumours can be 
curative. In the case of progression and metastatic spread (stage III and IV), which 
occurs compared to other types of cancer rather quickly, melanoma becomes rapidly 
fatal.  
 
 
Figure 1: As soon as transformed melanocytes start to grow out of control, the first stage of melanoma 
has begun. If the tumour is more than 1 mm thick, the patient has stage II melanoma. In stage III 
melanoma, the thickness of the tumour is no longer relevant to the grading:  the tumour has started to 
metastasise into local lymph nodes and vessels. Finally, as soon as the cancer has spread to other parts 
of the body (for example lung, liver and brain) stage IV is reached. Source: www.melanoma.org.nz 
 
 
The median survival time of patients in advanced stages is 9 months and the 5 year 
survival rate is less than 20% (Neuman 2008). Conventional treatments like 
chemotherapy and radiotherapy remain the first choice, despite poor clinical efficacy 
resulting in a very poor prognosis (Mitchell 2004; Neuman 2008). Due to this modest 
success rate, other treatment modalities are urgently required, and immunotherapy is 
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increasingly being applied for melanoma management over the last decade (Zeiser 
2012). Many immunotherapy trials targeting melanoma aim at two main goals: (i) 
generate or otherwise release from inhibition, a sufficient amount (generated either in 
vivo or in vitro) of activated anti-tumour T cells specific for tumour-associated 
antigens (TAAs) expressed by that individual patient´s tumour and furthermore (ii) 
these T cells must be in a position to circumvent tumours’ immune escape 
mechanisms.Tumour-associated antigens are exclusively expressed by or over-
expressed by transformed cells. Since the discovery of the first human TAA by van 
den Bruggen et al. (van der Bruggen 1991) much progress has been made in the 
search for possible TAAs, resulting in an ever-increasing list of tumour antigens, 
classified in different categories. Many of these antigens have been discovered on 
oncogenic melanocytes, making melanoma an appropriate model disorder for cancer 
immunotherapy. 
A well-known antigen that is overexpressed in many tumours including melanoma is 
the anti-apoptotic protein survivin. This protein, 142 amino acids long, was first 
described in 1997 by Ambrosini and colleagues (Ambrosini 1997). The anti-apoptotic 
function of survivin seems to be achieved by a blockade of the activation of the two 
effector caspases 3 and 7 by a direct interaction (Tamm 1998) making cells 
expressing survivin unsusceptible for apoptosis. Recent findings suggest that survivin 
is involved in promoting metastatic spread (McKenzie 2012) which makes it a 
suitable target antigen to treat late-stage melanoma. Differentiation antigens are 
only expressed by tumour cells and normal cells from the same lineage. Most of the 
antigens of this type were identified in melanoma patients, where only malignant and 
healthy melanocytes expressed the antigen. Examples of such differentiation 
antigens are glycoprotein 100 (gp100) and melanocyte antigen (Melan-A) / 
melanoma antigen recognised by T cells (MART-1). Melan-A was discovered 
independently by two working groups in 1994 (Coulie 1994; Kawakami 1994). It is a 
118-amino-acid-long protein with a single transmembrane domain which can only be 
found on melanocytes or on tumour cells which arise from them, making it an ideal 
target for melanoma immunotherapy (Romero 2002). The most targeted antigens for 
immunotherapy in general are the cancer/testis antigens (Caballero 2009). Aside 
from numerous cancer cells, they are exclusively expressed in immune-privileged 
tissue like testicular germ cells or placental trophoblasts. As germline cells lack MHC, 
therapies targeting cancer/testis antigens should only affect tumour cells and should 
avoid any autoimmune reactions. A prominent antigen of this category is melanoma-
associated antigen 3 (MAGEA3), which was discovered on melanoma but is also 
expressed by many other tumours at the mRNA and protein level. MAGEA3, a 
member of the MAGEA family, is 314 amino acids long and was first described in 
1994 (Gaugler 1994). Its function is not completely understood, but MAGEA proteins 
seem to interact with and block p53. Its level of expression is associated with 
prognosis, making MAGEA3 another appropriate target for cancer immunotherapy 
(Peled 2009). Another cancer/testis antigen that recently became the focus of 
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attention in cancer immunotherapy is New York esophageal squamous cell 
carcinoma 1 (NY-ESO-1), a 180-amino-acid-long protein of unknown function first 
described in 1997 (Chen 1997). In healthy individuals it is predominantly expressed 
in spermatogonia, the self-renewing stem cell population of germ cells in adult testis 
(Caballero 2009). It is expressed by many cancer types, including melanoma, where 
it is expressed in about 40% of patients. NY-ESO-1 is reported to be very 
immunogenic, hence, cellular responses in the peripheral blood and antibodies 
against NY-ESO-1 are frequently found, especially in late-stage melanoma patients. 
However, within the tumour, only a small number of cells express this antigen and the 
expression level can change with time. Its increasing relevance to immunotherapy 
was recently reviewed in detail by Cebon et al. (Cebon 2010). 
 
Not all types of TAAs are presented by the thymic epithelial cells or are only 
presented to a small extent. For that reason, high avidity naїve T cells that are 
capable of recognising these antigens might not always be deleted by negative 
selection and should generally be present in the organism. The generation of 
antigen-specific T cells in an immunological relevant amount should therefore 
generally be possible. 
 
(i) Tumor-specific T cells 
The increase in the number of TAA-reactive cells can be approached by active 
vaccination by administration of antigen-loaded APCs or in other ways, and by 
adoptive immunotherapy using T-cell transfer. For active vaccination, DNA (Wolchok 
2007) or RNA (Weide 2009) encoding the desired antigen, as well as peptides or the 
whole protein can be administered (Caballero 2009). The injected substance should 
be taken up by DCs, processed and presented to T cells in an immunogenic form. 
The same should happen if already-loaded DCs are injected into the patient 
(Lesterhuis 2008). Antigen-specific naïve or memory T cells must recognise their 
antigen and start clonal expansion and differentiation into effector T cells. These 
cells, as well as T cells administered by adoptive transfer (usually of autologous 
antigen-specific T cells first propagated in vitro and then reinfused into the patient 
(Rosenberg 2004)), should then attack those tumour cells that express the specific 
antigen(s). 
However, most clinical trials this far have not taken into account whether or not 
targeting certain antigens rather than others is more likely to result in a measurable 
clinical benefit. To take this into consideration, Cheever et al. screened the literature 
in order to prioritise TAAs for immunotherapy. According to parameters like 
immunogenicity and therapeutic effect, well-known TAAs were listed according to 
which antigens should be preferentially targeted (Cheever 2009). But even if the most 
promising TAAs are targeted, a clinical response will only be noted if the patients’ 
tumours actually express these TAAs. Some trials therefore analyse the expression 
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pattern of clinically removed tumours for each participating patient before therapy. 
But this approach has various disadvantages. It is very sophisticated, it cannot be 
applied to every patient but only to those with removable lesions and it is not known 
whether or not all metastases do constantly express the same antigens. One 
possibility to circumvent these drawbacks is the administration of a “danger signal” 
instead of a vaccination with a certain antigen. This signal, administered into the 
tumour, should attract immune cells to the site of injection and tumour degradation, 
enhance immune responses against antigens actually expressed by the tumour and 
lead to measureable tumour shrinkage optimally associated with prolonged survival. 
These clinical observations might also be associated with a detectable increase of 
antigen-specific T cells in the peripheral blood (as with those “Coley´s Toxins” 
successes). But not all melanoma patients, much less all cancer patients, can be 
treated with this method, as it requires visible tumours. Furthermore, none of these 
approaches consider that the tumour may still be able to inhibit the immune cells, 
even if they are highly antigen-specific and present in large numbers. 
 
(ii) Tumour escape mechanisms 
 
If we posit that the immune system can react to and control cancer 
(“immunosurveillance of cancer”), then most tumours must be definition have gained 
the ability to escape such immune surveillance (reviewed in detail by Campoli and 
Ferrone (Campoli 2008)). Multiple mechanisms contributing to tumour escape have 
been described over the years. In some tumours mutations within the cancer cells led 
to the downregulation of the major histocompatibility complex (MHC), resulting in a 
reduced or absent presentation of antigens.(Wang 2008) In other cases, the peptides 
derived from mutated proteins could not be embedded into the MHC molecule 
anymore, also resulting in an absence of antigen presentation. Production of 
inhibitory molecules, like cytokines Interleukin-10 (IL-10) or transforming growth 
factor ȕ (TGF-ȕ) which directly inhibit surrounding immune cells is also commonly 
observed (Derynck 2001; Dummer 1996). Tumours also stimulate 
immunosuppressive leukocyte populations like regulatory T cells (Tregs) or myeloid-
derived suppressor cells (MDSCs) to focus their suppressive activity on those 
immune cells that should normally destroy the neoplastic cell, in the same way that 
these cells maintain tolerance to other self-tissues (Murdoch 2008; Teng 2011). 
Other mechanisms include upregulated expression of inhibitory receptors like 
Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) or Programmed cell death protein 1 
(PD-1) by T cells as part of the normal immune control network usurped by tumours 
and leading to the inhibition of these antigen-specific T cells (Avogadri 2011; Flies 
2011).  
 
The circumvention of these latter escape mechanisms may be achievable by 
depleting the inhibitory cells (for example with agents like cyclophosphamide 
(Ghiringhelli 2007)), or by blockade of inhibitory molecules (for example with 
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neutralizing antibodies, here in a mouse model (Hagenbaugh 1997)) or the blockade 
of inhibitory receptors (for example with masking antibodies (Phan 2003)). Especially 
those recent clinical trials that targeted CTLA-4 and PD-1/PD-1 L have indeed 
yielded excellent clinical benefits, probably even cures in some patients (Hodi 2010; 
Topalian 2012). However, the fraction of patients responding favourably in any of 
these clinical trials has always been rather small, and many suffer serious side 
effects without receiving clinical benefit (Chmiel 2011; Minor 2009; Weber 2009). It is 
therefore of greatest interest to find independent biomarkers that predict a favourable 
outcome of cancer immunotherapy and provide mechanistic clues as to functional 
attributes required for maintaining long-term survival. Currently, only the plasma-level 
of Lactate dehydrogenase (LDH) is an accepted biomarker in many cancers, 
including melanoma (Balch 2001). Although other serum markers have been 
investigated for their prognostic power (Deichmann 1999; Tarhini 2009), none of 
them is widely accepted so far. Predictive markers are mostly absent thus far.   
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Aims of this thesis 
 
Treatment modalities for late-stage cancer patients are very limited and, especially in 
melanoma, immunotherapy is currently under intense investigation. Nonetheless, 
clinical benefit has only be observed in rare cases. It is therefore of greatest interest 
to find (a) highly effective and safe therapies that can easily applied to a large 
proportion of melanoma patients; (b) those target antigens that lead to the best 
clinical results and (c) predictive markers for successful treatment. The selection of 
the best target-antigens and the treatment of only those patients bearing certain 
markers associated with a good course of disease might reduce the number of 
unsuccessful therapies within one trial to a minimum. 
 
For this purpose, I first investigated the immunological impacts of intratumoural 
injected IL-2 for late-stage melanoma patients. Patients participating in this phase 2 
trial received the cytokine as a danger signal in order to increase anti-tumour immune 
responses. I analysed whether or not the patients showed any systemic treatment-
based increase of tumour-antigen-specific T cells in the peripheral blood. For that 
purpose, I assayed functional antigen-reactive T cells in the circulating blood using 
an intracellular cytokine staining (ICS) and flow cytometric analysis. In order to detect 
antigen responses in patients of any HLA type on the one hand and measure CD4 
and CD8 responses at the same time on the other, I used overlapping peptide pools, 
representing the whole antigen for expansion and restimulation of specific T cells. 
The use of polychromatic flow cytometry, in contrast to commonly-used methods to 
detect antigen-reactive T cells like ELISPOT or tetramers, allowed me additionally to 
analyse multiple parameters of the phenotype and function of the specific T cell on a 
single cell basis. 
 
Furthermore, I tried to identify biomarkers, which can independently predict the 
clinical outcome of an individual patient. Concerning melanoma, accumulating data 
suggested that the presence of certain antigen-reactive T cells within the tumour 
might be associated with a good clinical outcome, although this has never been 
observed for circulating cells from peripheral blood (Aarntzen 2010; Haanen 2006). I 
therefore sought T cells, specific for different melanoma-associated antigens, in the 
peripheral blood of stage IV melanoma patients. Patients with and without specific 
cells for each tested antigen, were clustered and analysed separately for survival. 
Additionally, I analysed the phenotype and function of each single antigen-specific T 
cell and investigated their possible impact on survival. 
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Results overview and discussion 
 
Intratumoural treatment with Interleukin-2 (Manuscript 1) 
51 stage III and IV melanoma patients were treated with IL-2, however, blood 
samples were unfortunately only available for one single patient with an exceptional 
good course of disease. I tested T-cell reactivity against four melanoma-associated 
antigens NY-ESO-1, Melan-A, MAGEA3 and survivin at the three different timepoints 
(before, during and after therapy). 
The injection of IL-2 into the tumour was well tolerated and highly effective. The 
therapy led to a complete local response of all treated lesions in 69% of patients and 
resulted in a 2 year survival rate of 77% for stage III and 53% for stage IV patients. 
Interestingly, even after an intratumoural treatment, an increase of functional antigen-
reactive T cells was observed in the peripheral blood, at least the one analysed stage 
III patient. This increase of antigen-reactive T cells was accompanied with an 
ongoing complete response, hinting at a possible systemic vaccination effect, which 
was also reported by others (Neville 2001). In another patient of this trial, vitiligo-like 
depigmentation as a possible sign of a specific immune response against 
differentiation antigens was observed. Furthermore, the possible systemic effect of a 
local application of IL-2 was also observed in preclinical trials, where the treatment 
led to the regression of untreated tumours and the generation of specific immunity 
(Van Es 2000). 
Early studies of systemic IL-2 treatments with long-term follow-up already 
documented that immunotherapy can be extremely effective in a small minority even 
in advanced melanoma patients (Atkins 1999). Although the significance of the 
results presented in the Tübingen patient is limited and they do not allow the drawing 
of strict conclusions, these data are additional hints for the crucial role of antigen-
reactive T cells, even for unspecific treatments like local IL-2 application. Although 
the results of this trial are very promising concerning complete responses and 
compatibility, it is still not an optimal treatment, as only visible lesions can be 
targeted. An improved approach to this trial, which was performed by the Department 
of Dermatology in Tübingen, used a fusion protein called L19-IL2, consisting of 
human IL-2 and an antibody fragment directed against the ED-B domain of 
fibronectin. This marker of angiogenesis is expressed in newly formed blood vessels, 
thus in cancer patients mainly at the tumour site. After being administered to the 
patient, the L19-IL2 will be distributed through the bloodstream and attach to newly-
formed blood vessels, and should reveal the therapeutic effect of IL-2. This approach 
will theoretically target both visible and non-visible lesions in the patient.. The 
enrolment of the patients started in June 2010 and ended in October 2012. In total, 
21 patients were recruited and we collected and cryopreserved PBMC samples from 
up to five different time points. It is planned to assay antigen-reactive T cells specific 
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for different melanoma-associated antigens at each time point. Furthermore we plan 
to investigate the role of certain immune cell types (naїve and memory T cells, 
dendritic cells, regulatory T cells, myeloid-derived suppressor cells etc.) and their 
potential influence on survival. Whether this approach will confirm the results from the 
first trial remains to be seen.   
Functional Specific T Cells in Stage IV Melanoma (Manuscript 2) 
In order to investigate the potential of antigen-specific T cells to predict the clinical 
outcome of end-stage melanoma patients, I assessed T cell responses against NY-
ESO-1, Melan-A, MAGEA3 and survivin in 84 patients with unresectable distant 
metastases and available clinical follow-up after T-cell analysis. Circulating antigen-
reactive T cells targeting TAAs were found to have indeed an important impact on 
survival. Univariate analysis showed that NY-ESO-1 (p=0.001) and Melan-A reactive 
T cells (p=0.011) both contributed to prognosis, and had an even stronger impact on 
survival than the M category (p=0.024) according to the American Joint Committee 
on Cancer (AJCC) staging system. Interestingly, therapies both prior and subsequent 
to blood draw did not have an impact on prolonged survival, clearly confirming the 
poor treatment options for late-stage melanoma patients. Patients with detectable 
MAGEA3-responsive T cells had a better course of disease than those without, but 
the observed survival differences were rather small and only just reached statistical 
significance (p=0.042). The presence of survivin-reactive T cells did not have an 
impact on survival (p=0.374). Finally, Multivariate Cox proportional hazards analysis 
revealed that only the presence of NY-ESO-1 (p=0.001) and Melan-A reactive T cells 
(p<0.001) were independently associated with a survival benefit. The median survival 
time (MST) for patients with NY-ESO-1 and/or Melan-A-reactive T cells was 21 
months, compared to 6 months for patients that did not possess these cells. 
A possible association between the presence of these cells and clinical benefit was 
also observed by others, albeit only in individual cases. It was reported that 6 of 8 
melanoma patients with impressive clinical results after anti-CTLA-4 treatment 
possessed NY-ESO-1-specific T cells (Yuan 2008). Another patient that was also 
treated with anti-CTLA-4 antibody, showed a durable complete response in all 
metastases, accompanied by a massive increase of Melan-A-specific T cells (Klein 
2009). Robbins et al. could reduce tumour mass in 5 of 11 melanoma patients by the 
adoptive transfer of genetically engineered T-cells, reactive to NY-ESO-1 (Robbins 
2011).  
Taken together, I confirmed the important role of NY-ESO-1 and Melan-A as target 
antigens of first choice for melanoma immunotherapy. The presence of these cells 
had an impact on survival superior to the AJCC M category and the applied therapy. 
Approaches that aim to generate or increase the amount of these specific cells 
should therefore be most probable to succeed. Furthermore, the absence of these 
cells might serve as a prognostic marker for stage IV melanoma.  
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Phenotype and Function of the antigen-specific T cell (Manuscript 3) 
As shown in Manuscript 2, the presence of NY-ESO-1 and Melan-A reactive T cells 
has an independent impact on survival. As a next step, I wanted to analyse in detail 
the phenotype and function of each antigen-reactive T cell population. ICS and multi-
colour flow cytometry revealed that both tested antigens were recognised 
predominantly by a certain subset, either CD4- or CD8-positive. When PBMCs were 
stimulated with overlapping peptides representing the whole NY-ESO-1 protein, it 
was mainly a CD4+ T-cell response that was triggered. 64% of all patients with NY-
ESO-1-specific T cells showed a pure CD4 response, 8% a pure CD8 response and 
28% both. On the other hand, Melan-A was predominantly recognized by CD8+ T 
cells. 59% of all patients with Melan-A-specific T cells showed a pure CD8 response, 
14% a pure CD4 response and 27% both. Furthermore, responses against these 
antigens led to slightly different cytokine patterns that mainly affected IL-2 secretion, 
which was more often released by NY-ESO-1-specific T cells.  
Interestingly, at least for Melan-A, both the phenotype and the function were 
associated with survival differences. Patients that possessed CD4+ Melan-A-reactive 
T cells showed a MST of 112 days, compared to 824 days for patients with CD8 T 
cell responses but without CD4 cell reactivity (p=0.0040). Concerning functional 
aspects of responses upon Melan-A stimulation, I observed that patients with specific 
T cells producing anti-inflammatory cytokines, had a markedly worse survival (MST: 
83 days) compared to patients whose T cells produced only pro-inflammatory 
cytokines (MST: 1976 days; p=0.0046). Both findings might probably reflect the 
activation of Melan-A-specific regulatory T cells, whose increasing role in melanoma 
management was recently reviewed in detail by Jacobs et al. (Jacobs 2012). 
Interestingly, a positive impact on survival mediated only by CD8+ Melan-A specific T 
cells was also observed by Khammari et al., where 7 of 14 melanoma patients 
treated with Melan-A-specific CTL clones, showed an objective response (complete 
and partial response or stable disease)(Khammari 2009). 
Both findings might have strong impact on the success of upcoming 
immunotherapeutic trials. Approaches, that aim to increase the amount of a certain 
cell type, for example CD8+ NY-ESO-1-specific T cells, might be more likely to fail. 
Vaccination with predicted MHC class-I epitopes, in order to increase the number of 
CD8+ cytotoxic T cells might not lead to as promising results as targeting CD4+ T 
cells could for this target antigen. Furthermore, many monitoring projects are aimed 
at detecting NY-ESO-1-specific T cells with multimers bearing MHC-I restricted 
epitopes, especially after systemic treatment like chemotherapy or application of 
cytokines. However, the presence of CD8+ NY-ESO-1-specific T cells may not be 
particularly informative. This might be one of the reasons for the deficiency of data 
showing correlations between clinical outcome and immunological findings. 
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For Melan-A, targeting the CD4+ T cells might even lead to worse survival. Many 
clinical trials, especially using DNA, RNA or whole protein vaccination, lead to both 
Melan-A-specific CD4 and CD8 responses, which according to the results presented 
here, may be counterproductive. I further observed that the function, here the release 
of certain cytokines, also had a strong impact on survival, at least for Melan-A. 
Patients whose T cells produced anti-inflammatory cytokines (IL-10 and/or IL-4) upon 
Melan-stimulation, even if they also produced pro-inflammatory cytokines, showed a 
dramatically reduced survival. Vaccination trials which also induce anti-inflammatory 
responses are, based on our results, unlikely to succeed. Hence, adoptive T-cell 
transfer of CD8+ Melan-A-specific T cells, preselected for mediating a solely pro-
inflammatory response might be the most promising immunotherapeutic approach for 
melanoma.  
Additionally, I also observed that only about 70% of all patients (69% for NY-ESO-1 
and 64% for Melan-A) responded upon antigen stimulation with the release of IFN-Ȗ. 
Commonly applied methods to detect antigen-specific T cells, like ELISPOT, that are 
usually restricted to the detection of this one cytokine, might therefore miss a 
considerable proportion of specific cells. 
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Concluding remarks 
Today, immunotherapy is a frequently used modality for treatment of advanced 
melanoma, although clinical benefits are only infrequently observed. Within this 
thesis I aimed at contributing data that might help to increase therapeutic success by 
finding promising treatment options, target antigens and predictive markers. In order 
to detect both CD4+ and CD8+ T cells, specific for various melanoma-associated 
antigens, I established a reliable method that can easily applied to patients of any 
HLA type. First applied in a study of local intratumoural application of IL-2 which 
demonstrated that this was a safe, easy applicable and most notably clinically 
successful method to treat melanoma, I observed that tumour-shrinkage was 
accompanied by an increase of peripheral antigen-specific T cells, at least in one 
patient. Although it can only be applied to patients with visible lesions, the obtained 
results are a rationale to further investigate and improve local IL-2-based therapies.  
I could confirm the encouraging role of NY-ESO-1 and Melan-A as target antigens of 
first choice for immunotherapy in a large cohort of stage IV melanoma patients. 
Interestingly, I observed that each of the four investigated antigens was preferentially 
recognized by a certain cell type. Furthermore, I discovered that phenotype and 
function of Melan-A-specific T cells have a huge impact on survival. Both findings 
would have remained unobserved with other methods to detect antigen-specific T 
cells. 
Most of these results were obtained from a homogeneous cohort of stage IV 
melanoma patients. Needless to say, the insights gained must be investigated in 
other melanoma patients, especially stage-III patients, as well. Late-stage melanoma 
patients have an extremely low life expectancy and the observed survival benefits for 
certain individuals might be even more significant in stage-III patients. Additionally, 
these data have to be investigated for other cancers expressing these two antigens. 
Especially NY-ESO-1, which is expressed by many other tumours (for example lung, 
breast and bladder carcinoma (Jungbluth 2001)), might be confirmed to be equally 
important. Furthermore, there are many other antigens that could play equally 
important roles for clinical benefit. Proteins that have characteristics (antigen 
category, level of expression, physicochemical properties etc.) similar to those of NY-
ESO-1 and Melan-A might prove to be additional crucial target antigens in cancer 
immunotherapy. 
Taken together, all the new insights obtained within this thesis might explain the lack 
of data that show correlations between clinical and immunological findings and 
should help to improve immunomonitoring and above all melanoma immunotherapy. 
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High response rate after intratumoral treatment 
with interleukin-2: Results from a phase 2 
study in 51 patients with metastasized 
melanoma. 
High Response Rate After Intratumoral
Treatment With Interleukin-2
Results From a Phase 2 Study in 51 Patients With Metastasized Melanoma
Benjamin Weide, MD1; Evelyna Derhovanessian, PhD2; Annette Pflugfelder, MD1; Thomas K. Eigentler, MD1;
Peter Radny, MD1; Henning Zelba2; Claudia Pfo¨hler, MD3; Graham Pawelec, PhD2; and Claus Garbe, MD1
BACKGROUND: Systemic high-dose interleukin-2 (IL-2) achieved long-term survival in a subset of patients with
advanced melanoma. The authors reported previously that intratumorally applied IL-2 induced complete local
responses of all metastases in >60% of patients. The objectives of the current study were to confirm those results in
a larger cohort and to identify patient or regimen characteristics associated with response. METHODS: Patients with
melanoma who had a median of 12 injectable metastases received intratumoral IL-2 treatments 3 times weekly until
they achieved clinical remission. The initial dose of 3 million international units was escalated, depending on the indi-
vidual patient’s tolerance. RESULTS: Forty-eight of 51 patients were evaluable. Only grade 1/2 toxicity was recorded.
A complete response that lasted 6 months was documented in 70% of all injected metastases. A complete local
response of all treated metastases was achieved in 33 patients (69%), including 11 patients who had between 20 and
100 metastases. Response rates were higher for patients who had stage III disease compared with patients who had
stage IV disease. No objective responses of distant untreated metastases were observed. The 2-year survival rate was
77% for patients with stage IIIB/IIIC disease and 53% for patients with stage IV disease. Efficacy and survival did not
differ between patients who had 20 lesions and patients who had <20 lesions. CONCLUSIONS: Intratumoral IL-2
treatment elicited complete local responses in a high percentage of patients. Further studies will be required to
investigate the mode of action of this treatment and its impact on survival. Cancer 2010;000:000–000. VC 2010
American Cancer Society.
KEYWORDS: melanoma, in-transit metastases, interleukin-2, intratumoral treatment, in situ vaccination.
Metastatic melanoma has an unfavorable prognosis, and treatment options are limited.1,2 In patients with stage III
melanoma, the objective of treating locoregional metastases is the complete removal of any detectable tumor manifesta-
tion. In patients who have many in-transit metastases, surgery often is no longer feasible. In a subset of patients who have
disease limited to 1 extremity, isolated limb perfusion can be applied but is associated with considerable toxicity.3 In
patients with stage IV melanoma and for patients who have unresectable metastases, palliative systemic treatments gener-
ally are preferred. However, surgical treatment is the first choice in stage IV if the patient can be rendered free of disease at
all knownmetastatic sites; and, in 10% to 20% of patients with stage IV disease, this therapeutic option seems to be associ-
ated with a clear survival benefit.4 Therefore, alternative direct treatment options are needed if disease is not completely
resectable.
Interleukin-2 (IL-2) has been used in immunotherapy against cancer since the early 1980s, applied either as a single agent5
or in combination with adoptively transferred, lymphokine-activated killer cells.6 Another approach is the adoptive transfer of
in vitro expanded, autologous tumor infiltrating lymphocytes7 followed by high-dose IL-2.8 A retrospective analysis of 8 trials
that used systemic high-dose IL-2 in patients with melanoma demonstrated response rates of 16%, including 6% complete
responses. Greater than 50% of the complete responders in those trials remained progression-free after 5 years.9 These data led
to US Food andDrug Administration approval of systemic high-dose IL-2 for the treatment of advancedmelanoma in 1998.
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Intratumoral application of drugs is an appealing
therapeutic concept, because high concentrations can be
achieved within the tumor, which may be essential to
attain the desired therapeutic effect. Furthermore, sys-
temic concentrations of locally applied drugs are low in
contrast to systemic treatments with the same agent,
resulting in comparably low toxicity. Several cytokines
have been used for intratumoral therapy with various
results.10-12 The first report that described the regression
of melanoma metastases after intratumoral IL-2 treatment
was published in 1994.13 On the basis of those findings,
we initiated a pilot study on 24 patients and observed
complete responses of all treated metastases in >60%. In
contrast to systemic, high-dose therapy, intratumoral
application was associated with low toxicity.14 The objec-
tives of the current study were to confirm our previous
results in a larger cohort and to identify relevant patient or
regimen characteristics associated with response to treat-
ment and with overall survival.
MATERIALS AND METHODS
Patients
The study protocol (National Clinical Trials [NCT] clini-
caltrials.gov identifier NCT00204581) was approved by
the local ethics committees, and patients were treated only
after written informed consent was obtained. Inclusion
criteria comprised age>18 years, histopathologically pro-
ven malignant melanoma, the presence of injectable der-
mal or subcutaneous metastases either in clinical stage III
or clinical stage IV, and an expected survival >3 months.
Excluded were pregnant or lactating women and patients
with severe cardiac disease (New York Heart Association
III and IV), alanine and aspartate aminotransferase levels
>3 times above the upper limit of normal, creatinine
>1.5 times above the upper limit of normal, and concom-
itant systemic therapy with steroids. Patients who
required systemic chemotherapeutic treatment for meta-
static disease and patients who had locoregional lymph
node metastases were excluded. Previous systemic chemo-
therapy was allowed.
Study Design and Treatment
The trial had the design of an open, prospective phase 2
study. Patients were recruited at 2 study sites (Tuebingen
and Homburg, Germany). For preparation of IL-2, 18
million international units (MIU) of recombinant human
IL-2 (Proleukin; Novartis, New York, NY) were dissolved
in 6 mL glucose 5% supplemented with 0.2% human se-
rum albumin. IL-2 was injected intratumorally using 30-
gauge needles for superficial injections and 27-gauge nee-
dles for deep injections, and single doses ranged between
0.3 MIU and 6 MIU, depending on the lesion size. One
injection per lesion was applied for doses per lesion up to
3 MIU, and 2 injections were applied for doses >3 MIU
per lesion. Treatment was initiated at 3 MIU IL-2 daily,
and the dose was escalated by 1.5 MIU each treatment
day up to the desired total dose according to the number
of lesions and treatment guidelines (Table 1), provided
that tolerability was maintained. The total daily dose was
divided between all injectable lesions. For deep soft tissue
metastases, sonography was used to guide injections. Up
to 25 lesions were treated simultaneously; however, if more
lesions were present, then they were treated alternately or
subsequently. The treatment schedule was 3 times weekly on
an outpatient basis. Treatment was terminated when clinical
regression and/or necrosis of metastases was evident or if pro-
gression occurred that no longer was manageable by ongoing
IL-2 injections. Adverse events were graded according to the
CommonToxicity Criteria (version 3).
Response Evaluation
Every treated metastasis was evaluated separately regard-
ing clinical response between 4 weeks and 8 weeks after
stopping IL-2 treatment and every 3 months thereafter.
The following definitions were used: a complete response
(CR) of a treated lesion was defined as the disappearance
of any evidence of vital tumor and lack of tumor growth
after stopping injections over a period of at least 6 months.
A partial response (PR) was defined as a decrease 30%
in the greatest dimension (longest diameter [LD]). Stable
disease (SD) was defined as neither sufficient shrinkage to
Table 1. Treatment Guidelines
Minimal
Single
Dose
of IL-2 per
Lesion, MIU
Volume
Stock
Solution,
mL
Duration of
Treatment,
wk
Size of
Individual
Lesion, mm
<2 0.3 0.1 2
<5 0.6 0.2 2
<10 1.2 0.4 3
<20 3.0 1.0 4
20 6.0 2.0 4
IL-2 indicates interleukin-2; MIU, million international units.
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qualify for a PR nor sufficient increase to qualify as pro-
gressive disease (PD). PD was defined as an increase
20% increase in the LD of the lesion. Subcutaneous me-
tastases were evaluated by sonography. In nondistinctive
cases (eg, if there was residual pigmentation), biopsies
were taken for histopathologic confirmation of response.
Statistical Analysis
Statistical analyses were conducted using the SPSS 15.0
software package (SPSS Inc., Chicago, Ill). Follow-up was
defined as the time from the first IL-2 injection to the
date of last contact or death. For survival analyses, only
deaths that were caused by melanoma were considered.
The last survival update was done for all patients in April
2009. Kaplan-Meier analyses were performed to estimate
overall survival. Differences in response rates were calcu-
lated by using a 2-tailed Fisher exact test.
Analysis of Specific Cellular Immune
Responses
For 1 patient, the frequency of antimelanoma T cells was
measured by flow cytometric analysis at different time
points. Briefly, peripheral blood mononuclear cells
(PBMCs) were incubated for 11 days in X-Vivo 15 (Lonza
Verviers, Braine-l’Alleud, Belgium) with mixtures of over-
lapping peptides (PepMix; JPT Technologies, Berlin,
Germany) that spanned the whole sequence of Melan-A,
cancer-testis antigen (NY-ESO1), melanoma-associated
antigen 3 (MAGE-A3), Survivin, and membrane protein
M1/nucleocapsid protein from influenza virus, each at a
concentration of 1 lg/mL. On Day 4, IL-2 was added
(40 U/mL; Chiron Behring GmbH,Marburg, Germany).
On Day 11, autologous PBMCs as stimulator cells were
labeled with 5 lM carboxy fluorescein succinyl ester
(CFSE) (Invitrogen, Karlsruhe, Germany) and incubated
for 6 hours with each peptide mixture mentioned above.
Cultured T cells were harvested and incubated at a 1:2
ratio with unpulsed or peptide-pulsed stimulator cells in
the presence of 1 lL/mLGolgi-Plug (BD Biosciences, Mis-
sissauga, Ontario, Canada) for 12 hours. Thereafter, the
cells were incubated with ethidium monoazide (EMA)
(Invitrogen) followed by fixation and permeabilization
with CytoFix/CytoPerm (BD Biosciences) and staining
with cluster of differentiation (CD) 3 antibody (anti-
CD3)-Pacific Orange (Caltag; Invitrogen), anti-CD4-peri-
dinin chlorophyll protein complex, and anti-CD8-allophy-
cocyanin-indocyanine 7 (BD Biosciences). Intracellular
IFN-c staining was done with a phycoerythrin/indocyanine
7-conjugated antibody (BD Biosciences) according to the
manufacturer’s instructions and was measured immediately
using a BD LSR II flow cytometer (BD Biosciences). Flow
cytometric data analysis was performed using FlowJo soft-
ware (Tree Star, San Carlos, Calif) after the exclusion of
CFSE-positive stimulator cells and EMA-positive dead
cells. IFN-c secretion was considered antigen-specific only
when the frequency of IFN-positive T cells that responded
to peptide-pulsed PBMCs was at least 2 times greater than
the frequency of IFN secretion in response to the negative
control (unpulsed PBMCs).
RESULTS
Patients and Treatments
In total, 51 patients (44 in Tuebingen and 7 in Homburg)
were enrolled between August 2003 and November 2007
and completed IL-2 treatment by December 2007. Two
patients were excluded after they provided informed con-
sent, because progressive visceral disease that was detected
at baseline staging diagnostics required chemotherapy.
For 1 patient, neither treatment nor follow-up data were
available. The baseline data from the 48 remaining
patients are summarized in Table 2. The median patient
Table 2. Patient Characteristics
Characteristic No. of Patients %
Sex
Men 21 44
Women 27 56
Stage
Stage III 33 69
IIIB 17
IIIC 16
Stage IV 15 31
M1a 8
M1b 3
M1c 4
Visceral metastases present 5
Site of treated metastases
Dermal only 28 58
Subcutaneous only 11 23
Combined 9 19
No. of treated metastases
<20 33 69
20 15 31
Previous therapies
Surgery in stage III/IV 28 58
Limb perfusion 2 4
Radiotherapy 2 4
Adjuvant interferon alpha 14 29
Systemic chemotherapy 11 23
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age was 69 years (range, 37-88 years). Thirty-three
patients were treated in stage III, and 15 patients were
treated in stage IV. Among the patients with stage IV dis-
ease, 5 patients had lymph node/visceral metastases that
were not accessible to local IL-2 treatment. Among the
patients with stage III disease and the remaining 10
patients with stage IV disease, all metastases were accessi-
ble for injections. Most patients had received previous
extensive therapy. Twenty-eight patients developed
locoregional recurrences after undergoing surgery for met-
astatic disease. The last surgery occurred 8 weeks before
the start of IL-2 therapy for 14 of 28 patients, and 22
of 28 patients underwent 2 previous surgeries. In 5
patients, limb perfusion or radiotherapy also was per-
formed. Previous systemic treatments with interferon
alpha (IFN-a) (11 patients), chemotherapy (8 patients),
or both modalities subsequently (3 patients) had been
applied before IL-2 treatment was initiated. The median
duration of IL-2 treatment was 6 weeks (range, 1-32
weeks; some patients received several subsequent treat-
ments for newly developing metastases), and the applied
median total dose was 68.5 MIU IL-2 (range, 13.5-548.1
MIU). The median number of metastases treated per
patient was 12. The highest daily dose was 16MIU IL-2.
Toxicity
All 48 patients were included in the analysis of toxicity.
The treatment generally was tolerated well, and only grade
1 and 2 toxicity was recorded. Intratumoral IL-2 therapy
almost always caused an inflammatory injection site reac-
tion (local swelling and erythema) followed by a selective
necrosis of the tumor tissue that generally did not affect
the surrounding normal tissue. Injection pain also was fre-
quent but was manageable by the application of a local
anesthetic cream and oral metamizole. The majority of
patients experienced fever (58%) that could be controlled
easily by acetaminophen. Fatigue (36%) and nausea
(34%) usually were mild and of short duration. Frequent
adverse events are presented in Figure 1. Adverse events
that were observed in <10% of patients but that were at
least possibly related to the treatment included stomach
pain, myalgia, and headache (in 4 patients each); itching
exanthema (in 3 patients); dry oral mucosa (in 2 patients);
pruritus (in 2 patients); hair loss (in 1 patient); and diar-
rhea (in 1 patient). One patient presented with general-
ized urticaria, which was abated by antihistaminic
treatment and did not recur after further IL-2 treatments
under continued prophylactic medication. One patient
observed worsening of a pre-existing atopic dermatitis,
and 1 patient reported a single episode of mild cardiac
arrythmia. One patient presented with vitiligo-like depig-
mentation around the treated metastases (Fig. 2).
Figure 1. Frequent adverse events are illustrated in 48
patients with metastatic melanoma who received intertu-
moral interleukin-2.
Figure 2. Vitiligo-like depigmentation is observed in an inter-
leukin-2–treated area in a patient after treatment.
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Clinical Responses to IL-2 Treatment
In total, 894 of 917 separately treated metastases (97.5%)
could be evaluated for local tumor response (Table 3).
The analysis revealed a 78.7% CR rate, a 0.7% PR rate,
16.3% stable metastases, and 4.3% progressive lesions.
Differences regarding the rate of complete local responses
of injected metastases were detected between stage III ver-
sus stage IV (96.9% vs 54.8%, respectively; P < .0001)
and the absence or presence of visceral metastases (92.5%
vs 16.5%, respectively; P< .0001). Furthermore, efficacy
differed significantly between dermal versus subcutaneous
injected lesions both for stage III disease (CR rate: 97.9%
vs 90.3%, respectively; P ¼ .0034) and stage IV disease
(CR rate: 56.7% vs 34.4%, respectively; P ¼ .0247). No
objective responses of noninjected distant lesions were
observed in 5 patients with stage IV disease who had vis-
ceral metastases. Figure 3 illustrates the clinical course of
3 patients who received intratumoral IL-2 treatment.
In 33 patients (69%) a complete local response of all
treated metastases was achieved with a better outcome for
patients who had stage III disease compared with patients
who had stage IV disease (82% vs 40%; P ¼ .0067). Of
these, 32 patients were completely free of recognizable tu-
mor after treatment. The percentage of patients with a
complete local response of all treated metastases did not
depend on the number of treated lesions (73% for
patients who had 20 treated metastases vs 66% for
patients who had<20 treated metastases; P¼ .7458).
Overall Survival
The median follow-up was 25 months from the start of
IL-2 treatment (range, 4-68 months; median, 14 months
for patients who died of their disease and 32.5 months for
all others). Overall survival rates were promising for all
patients (Fig. 4A). We did not record any deaths from
melanoma later than 25 months after starting treatment,
indicating a considerable chance for long-term survival in
patients who survived the first 2 years. Patients who had
stage III disease, as expected, had higher overall survival
rates compared with patients who had stage IV disease
(77% vs 53% after 2 years). It is noteworthy that overall
survival for the subgroup of patients who had stage IV
Table 3. Treatment Response
No. of Metastases Percentage
CR PR SD PD CR PR SD PD Pa
Response per metastases (n¼894) 704 6 146 38 78.7 0.7 16.3 4.3
Stage III metastases (n5509) 493 3 5 8 96.9 0.6 1 1.6
<.0001
Stage IV metastases (n5385) 211 3 141 30 54.8 0.8 36.6 7.8
Visceral metastases not present (n5732) 677 4 35 16 92.5 0.5 4.8 2.2
<.0001
Visceral metastases present (n5162) 27 2 111 22 16.7 1.2 68.5 13.6
Stage III dermal metastases (n5437) 428 3 4 2 97.9 0.7 0.9 0.5
.0034
Stage III subcutaneous metastases (n572) 65 0 1 6 90.3 0 1.4 8.3
Stage IV dermal metastases (n5353) 200 0 131 22 56.7 0 37.1 6.2
.0247
Stage IV subcutaneous metastases (n532) 11 3 10 8 34.4 9.4 31.3 25
CR indicates complete response; PR, partial response; DS, stable disease; PD, progressive disease.
a The calculation of differences between 2 groups of patients was based on the CR rate.
Figure 3. Clinical findings are shown before, during, and after
intratumoral treatment with interleukin-2 (IL-2). (A) A man
aged 59 years with stage IIIB melanoma had 17 lesions
treated and has remained progression free since the start of
IL-2 treatment in August 2003. Note the vitiligo-like depig-
mentation after therapy (right). (B) A woman aged 88 years
with stage IIIB melanoma had 25 lesions treated and
remained progression-free from the start of IL-2 treatment in
December 2004 until her death in January 2009 (not mela-
noma-related). (C) A woman aged 47 years with stage IV
melanoma (M1a) had 44 lesions treated and has remained
progression free since June 2006.
]
]
]
]
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disease without visceral metastases was comparable to that
for patients who had stage III disease (Fig. 4A, dotted line).
The long-term outcome did not depend on the number of
treated metastases, because the overall survival for 15
patients who had 20 metastases was as good as that for
the other 33 patients who had<20metastases (Fig. 4B).
Specific Cellular Immune Responses
For 1 additional patient with stage III disease who was
treated in 2008, peripheral blood samples were collected
before IL-2 injections, 4 weeks after starting treatment,
and 2 months after ending treatment. This woman had 19
dermal metastases, received 11 treatments (cumulative
dose 55 MIU IL-2), and had an ongoing complete clinical
and histopathologic response after therapy. There was a
significant increase (3 times greater than background) in
IFN-c–positive, CD8-positive T cells that were specific
for MAGE-A3, Melan-A, and NY-ESO-1 during treat-
ment, and the increased frequency of MAGE-A3–specific,
CD8-positive T cells remained present even 2 months af-
ter the end of treatment; whereas the frequency of influ-
enza-specific, IFN-c–positive T cells remained constant at
all 3 time points (data not shown). Similarly, there was a
marked increase (almost 2 times greater than background)
in the frequency of IFN-c–positive, CD4-positive T cells
that were specific for MAGE-A3 during and after therapy,
but the frequency of CD4-positive T cells that were spe-
cific for other antigens did not change significantly (Fig.
5).
DISCUSSION
Confirming the results from our pilot study in the cur-
rent, larger trial, we again observed a complete local
response of all treated metastases in 69% of patients (82%
of patients with stage III disease and 40% of patients with
stage IV disease). It is well established that systemic, high-
dose IL-2 treatment is effective in a subset of patients with
melanoma, and this subgroup appears to represent most
patients who have soft tissue metastases. Phan et al
reported a 53% response rate to systemic IL-2 treatment
in a subgroup of 28 patients with subcutaneous and der-
mal metastases.15 Thus, the observed efficacy in our cur-
rent trial most likely was a result of the high intratumoral
IL-2 concentration, which also has been described in ani-
mal models after intratumoral treatment.16
In contrast to systemic IL-2 treatment accompanied by
severe toxicity, intratumoral IL-2 treatment is well tolerated.
The good tolerability of this treatment obviously depends on
the small amounts applied, with little systemic leakage, and
on the application of treatment only 3 times weekly. This is
reflected in the complete lack of any premature terminations
of treatment because of toxicity in our study.
In the current study, we also tried to identify the
patient characteristics that were associated with outcome.
We observed that the presence of visceral metastases that
could not be injected also was associated with a low local
response rate of the injected metastases (CR, 16.7% of me-
tastases; PR, 1.2% of metastases). This is an interesting ob-
servation and raises the issue of differences in the immune
responsiveness of patients who have visceral metastases.
These patients probably should be regarded as ineligible for
this treatment. Efficacy also was greater for dermal metasta-
ses than for subcutaneous metastases in both stage III and
Figure 4. Overall survival was calculated from the start of
interleukin-2 treatment. Survival probabilities calculated
according to the Kaplan-Meier method are illustrated accord-
ing to (A) disease stage and (B) the number of metastases at
the start of treatment. Short vertical lines represent censored
events.
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stage IV disease. The greater size of subcutaneous lesions
may help explain this finding, because we generally observed
greater treatment efficacy in smaller metastases. Conversely,
injections into subcutaneous metastases usually were applied
after ultrasound-guided marking of the localization on the
skin surface. This occasionally may have led to peritumoral
injections instead of intratumoral injections, which are
known to be less effective.17 Another possible explanation
may be that the dermis provides a better environment for
inflammatory reactions than subcutaneous tissues.
The 2-year overall survival probability for patients
who had stage IIIB/IIIC disease was 77% (stage IIIB,
94%; stage IIIC, 61%), and it was 53% for patients who
had stage IV disease after starting local IL-2. It is notewor-
thy that the presence of a large number of metastases was
not associated with a poorer long-term outcome than the
presence of fewer metastases. In the current study, we
treated 13 patients who had 20 metastases but no
visceral lesions. Remarkably, 11 or those patients have
remained free of any residual tumor after stopping IL-2
treatment despite the initially high number of lesions.
Seven patients have remained free of any recurrence over
the follow-up period, and only 3 patients have died from
melanoma to date (data not shown). This subgroup of
patients often is regarded as unresectable because of the
high number of metastases. Therefore, systemic chemo-
therapy (with response rates <30% and without any pro-
ven benefit on overall survival) otherwise generally would
be the only alternative treatment option for such patients.2
The exact mode of action of IL-2 is unknown. One
hypothesis is that lymphokine-activated killer cells are
induced by IL-2 and subsequently destroy the tumor by
direct lysis.6 Indeed, histopathologic evaluation of biop-
sies taken from IL-2–treated metastases revealed a dense
intratumoral and peritumoral lymphocytic infiltrate. We
observed that tumor cells were undergoing apoptosis and
that the mononuclear infiltrate mainly consisted of CD8-
positive, CD4-positive T cells, and (only to a minor
extent) natural killer cells.14 The favorable long-term out-
comes that we observed suggest a possible beneficial sys-
temic mode of action induced by the local treatment.
Systemic responses after locally applied intratumoral IL-2
have been described to date in various animal models.
Maas et al treated lymphoma-bearing mice and reported
the regression of distant uninjected lesions after intratu-
moral treatment. The same IL-2 doses given systemically
were far less effective.18 Van Es et al studied a trans-
planted rabbit carcinoma model and demonstrated that
Figure 5. Specific immune responses are illustrated. Circulating interferon-c (IFN-c)-positive (IFN-cþ) T cells from 1 patient were
analyzed before, during, and after therapy and were measured by flow cytometry. (A) The percentages of MAGE-A3, Melan-A,
NY-ESO-1, and Survivin-specific CD8þ T cells (left) and CD4þ T cells (right) are illustrated. Cells were stimulated either with auto-
logous peripheral blood mononuclear cells that were pulsed with corresponding peptides or with unpulsed cells as a negative
control. (B) Corresponding dot plots of MAGE-A3–specific IFN-cþ T cells are shown at baseline and before and after treatment.
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peritumoral IL-2 induced complete regressions of
untreated contralateral tumors. A second challenge of
the cured animals resulted in tumor rejection, suggesting
the generation of specific immunity.19 In accordance with
these preclinical observations, we demonstrated vitiligo-like
depigmentation in 1 patient as a sign for the induction of a
specific immune response directed against differentiation
antigens. In another patient, a marked increase in circulating
antimelanoma T cells was observed, hinting at a possible sys-
temic vaccination effect.20 The presented trial was planned
as a local treatment option for unresectable patients that did
not take into account possible systemic modes of action. We
only performed specific immune monitoring in 1 patient.
Therefore, the significance of these data are limited, and
additional patients need to be analyzed in subsequent trials.
We are aware that the design of the current study does not
allow us to reach any definite conclusions regarding long-
term outcome, because the trial did not include a control
group and may have been influenced by a positive selection
bias. Moreover, a potential positive systemic effect of locally
applied IL-2 is questionable because of the inability of the
treatment to induce regression of distant metastases that
were not treated directly in 5 of our patients. Nevertheless,
our observations strongly support further pursuit of this
therapeutic approach in a randomized trial that includes a
control (surgery-alone) group.
In conclusion, intratumoral IL-2 treatment eli-
cited complete local responses of all injected lesions in
69% of patients, especially in patients without visceral
metastases. A high proportion of patients could be
rendered completely free of injected metastases using
this approach. A large number of metastases was not
associated with a poorer long-term outcome. There-
fore, intratumoral IL-2 may be regarded as a promis-
ing therapeutic option for a selected subgroup of
patients with melanoma and also may be feasible for
the treatment of other accessible solid tumor entities.
Further studies will be required to investigate the
mode of action and the impact on survival of intratu-
moral treatment with IL-2.
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A B S T R A C T
Purpose
To analyze the prognostic relevance of circulating T cells responding to NY-ESO-1, Melan-A,
MAGE-3, and survivin in patients with melanoma with distant metastasis.
Patients and Methods
We examined 84 patients with follow-up after analysis (cohort A), 18 long-term survivors with an
extraordinarily favorable course of disease before analysis ( 24 months survival after first
occurrence of distant metastases; cohort B), and 14 healthy controls. Circulating antigen-reactive
T cells were characterized by intracellular cytokine staining after in vitro stimulation.
Results
In cohort A patients, the presence of T cells responding to peptides from NY-ESO-1, Melan-A, or
MAGE-3 and the M category according to the American Joint Committee on Cancer classification
were significantly associated with survival. T cells responding to NY-ESO-1 and Melan-A (hazard
ratios, 0.29 and 0.18, respectively) remained independent prognostic factors in Cox regression
analysis and were superior to the M category in predicting outcome. Median survival of patients
possessing T cells responding to NY-ESO-1, Melan-A, or both was 21 months, compared with 6
months for all others. NY-ESO-1–responsive T cells were detected in 70% of cohort A patients
surviving  18 months and in 50% of cohort B patients. Melan-A responses were found in 42%
and 47% of patients in cohorts A and B, respectively. In contrast, the proportion was only 22% for
NY-ESO-1 and 23% for Melan-A in those who died within 6 months.
Conclusion
The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent
prognostic impact on survival in advanced melanoma. Our findings support the therapeutic
relevance of Melan-A and NY-ESO-1 as targets for immunotherapy.
J Clin Oncol 30. © 2012 by American Society of Clinical Oncology
INTRODUCTION
The prognosis of patients with melanoma with unre-
sectable distant metastasis is poor, with a median sur-
vival of 9 months and 5-year survival of less than 20%.1
Lactate dehydrogenase (LDH) is the only well-
accepted serum biomarker in malignant melanoma. It
has been part of the American Joint Committee on
Cancer (AJCC) staging system since 2001.2-4 Other se-
rummarkersofmelanomacellorigin(eg,S100b,MIA)
have been investigated, but none are as yet widely ac-
cepted.5,6 Current peripheral blood biomarkers do not
allowtheidentificationofeitherpatientswiththeworst
prognosis or patients who may survive longer term.
In contrast to factors related to or derived from
the melanoma cell itself, immune-related biomark-
ers have rarely been described. Long-term survival
even in advanced disease was observed in a subset of
patients after treatment with interleukin-2 (IL-2)7
or ipilimumab.8 Those agents are believed to act
indirectly through the immune system. Immune
system–based prognostic markers might therefore
be useful in tumor-free patients to indicate the like-
lihood of long-term survival and may serve as pre-
dictive markers for response to immunotherapies.
Thus far, interferon alfa (IFN-) –induced au-
toantibodies and pretherapeutic serum cytokine
profiles have been described to predict outcome af-
ter treatment with IFN-.9,10 C-reactive protein,
IL-6, and IL-10 concentrations in serum have like-
wise been reported to serve as prognostic markers,
but their specificity seems limited.11-14 The humoral
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immune response against TA90 has been found to be prognostically
relevant in patients receiving an allogeneic melanoma vaccine.15,16
Whether the frequency of circulating regulatory T cells, natural killer
cells, myeloid-derived suppressor cells, or others does have prognostic
impact has only been analyzed in small cohorts of patients with mel-
anoma, with equivocal results.17-20
Specific immunotherapy of solid tumors mainly aims to induce
or increase the number of T cells directed against epitopes of tumor
antigens; it has been under intense investigation. Although a high
frequency of circulating antigen–specific T cells after vaccination has
been reported in many trials, correlations with clinical outcome have
been notoriously inconclusive.21-23 On the other hand, a direct impact
of these types of cells has been demonstrated by impressive clinical
responses in up to 70% of patients with melanoma on adoptive trans-
fer of tumor-infiltrating lymphocytes or T-cell receptor–transduced
lymphocytes.24,25 T cells specific for melanoma-associated antigens
have also been detected in the peripheral blood of patients with mel-
anoma without vaccination or other immunotherapies.26,27 So far,
only a single, tetramer-based study has analyzed the correlation of
spontaneously occurring circulating specific T cells in patients with
melanoma with survival, but it did not apply functional assays and
failed to report a prognostic impact.28
The aim of the present study was to investigate the prognostic
relevance of functional circulating T cells responding to the tumor-
associated antigens NY-ESO-1, Melan-A, MAGE-3, and survivin on
overall survival of patients with melanoma with distant metastasis.
PATIENTS AND METHODS
Patients
Cryopreserved peripheral blood mononuclear cells (PBMCs) were ac-
cessed from the Departments of Dermatology, University Medical Centers of
Tu¨bingen and Essen (Tu¨bingen and Essen, Germany), and the Department of
Medical Oncology and Immunotherapy, University Hospital of Siena, (Siena,
Italy). Peripheral blood lymphocytes were obtained from the Nijmegen Centre
for Molecular Life Sciences (Nijmegen, the Netherlands). Additional fresh
blood samples were received from the Blood Bank and Department of Derma-
tology, University Medical Center of Tu¨bingen. PBMCs were immediately
isolated from fresh blood by Ficoll-Hypaque density gradient centrifugation
and cryopreserved until use.
Available biobanked samples from patients with melanoma who
fulfilled the following criteria were obtained from the clinical centers:
cohort A, patients with unresectable distant metastases at the time of blood
draw and available follow-up data after blood draw; cohort B, no radiologic
or clinical evidence of disease at blood draw,  24 months since first
diagnosis of distant metastasis, history of visceral metastasis other than
lung or elevated LDH (long-term survivors); cohort C, no history of
cancer. All patients provided written informed consent for biobanking.
This study was approved by the ethics committee in Tu¨bingen (approvals
147/2011BO2 and 432/2011BO2).
Detection of Antigen-Responsive T Cells
T-cell responses against NY-ESO-1, Melan-A, MAGE-3, and survivin
were measured as described previously.29 Briefly, cells were stimulated
with protein-spanning overlapping peptides (1 g/mL; PepMix; JPT Pep-
tide Technologies, Berlin, Germany). After culture for 12 days, T cells were
restimulated at a ratio of 1:2 with autologous, carboxyfluorescein succin-
imidyl ester (CFSE) –stained PBMCs (5 mol/L CFSE; Invitrogen,
Karlsruhe, Germany) either unpulsed (negative control) or presenting one
of the antigens in the presence of Golgi-Plug (1 L/mL; BD Biosciences,
Toronto, Ontario, Canada). After 12 hours of coincubation, Fc receptors
Table 1. Patient Characteristics and Results of Survival Analysis Based on
Kaplan-Meier Method
Factor
Patients
1-Year Survival
Rate
P†No. % % Dead % 95% CI
Age, years .755
 55 41 48.8 73.2 35.8 20.9 to 50.7
 55 43 51.2 81.4 50.1 35.0 to 65.2
Sex .715
Male 56 66.7 75.0 40.1 27.0 to 53.2
Female 28 33.3 82.1 48.9 30.1 to 67.7
M category .024
M1a or b 22 26.5 68.2 58.7 37.9 to 79.5
M1c 61 73.5 82.0 36.3 24.0 to 48.6
NY-ESO-1–responsive T cells  .001
Present 36 42.9 61.1 63.3 47.4 to 79.2
Absent 48 57.1 89.6 27.5 14.6 to 40.4
Melan-A–responsive T cells .011
Present 22 31.9 63.6 59.1 38.5 to 79.7
Absent 47 68.1 83.0 37.2 23.1 to 51.3
Missing 15 80.0 37.5 12.0 to 63.0
MAGE-3–responsive T cells .042
Present 38 60.3 71.1 49.3 33.2 to 65.4
Absent 25 39.7 92.0 28.0 10.4 to 45.6
Missing 21 71.4 49.5 27.2 to 71.8
Survivin-responsive T cells .374
Present 8 15.1 62.5 58.3 21.8 to 94.8
Absent 45 84.9 80.0 34.4 20.3 to 48.5
Missing 31 77.4 51.6 34.0 to 69.2
Prior systemic treatments
Anti-CTLA4 .218
Yes 9 10.7 44.4 64.8 32.5 to 97.1
No 75 89.3 81.3 40.2 28.8 to 51.6
Other immunotherapy .260
Yes 39 46.4 74.4 49.7 33.6 to 65.8
No 45 53.6 80.0 37.6 23.5 to 51.7
Monochemotherapy .505
Yes 22 26.2 72.7 36.2 14.4 to 58.0
No 62 73.8 79.0 45.1 32.8 to 57.4
Polychemotherapy .802
Yes 7 8.3 71.4 35.7 74.5 to 74.5
No 77 91.7 77.9 43.5 32.3 to 54.7
Biochemotherapy .447
Yes 7 8.3 57.1 53.6 14.2 to 93.0
No 77 91.7 79.2 42.0 30.8 to 53.2
Subsequent systemic
treatments
Anti-CTLA4 .421
Yes 18 21.4 61.1 54.5 31.2 to 77.8
No 66 78.6 81.8 39.9 27.9 to 51.9
Other immunotherapy .656
Yes 17 20.2 88.2 47.1 23.4 to 70.8
No 67 79.8 74.6 42.0 30.0 to 54.0
Monochemotherapy .171
Yes 36 42.9 86.1 37.6 21.5 to 53.7
No 48 57.1 70.8 47.0 32.7 to 61.3
Polychemotherapy .164
Yes 19 22.6 89.5 35.1 13.0 to 57.2
No 65 77.4 73.8 45.4 33.2 to 57.6
Biochemotherapy .713
Yes 12 14.3 91.7 66.7 40.0 to 93.4
No 72 85.7 75.0 39.0 27.4 to 50.6
Two- and 3-year survival rates provided in Appendix Table A1, online only.
†P values are results of log-rank tests, excluding patient cases with missing values.
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were blocked with Gamunex (human immunoglobulin; Bayer, Le-
verkusen, Germany), and dead cells were labeled with ethidium monoa-
zide (Invitrogen, Karlsruhe, Germany). Cells were fixed and permeabilized
with CytoFix/CytoPerm (BD Biosciences) and stained with the following
antibodies: CD3/Qdot655 and anti-CD4/Pacific Orange (Invitrogen);
CD8/APC-H7, IL-4/APC, and IFN-/PE-Cy7 (BD Biosciences); TNF/PE
(Miltenyi Biotec, Bergisch Gladbach, Germany); IL-10/Pacific Blue and IL-
17/PerCP-Cy5.5 (eBioscience, San Diego, CA); and IL-2/Alexa700 (BioLeg-
end, San Diego, CA). Samples were measured immediately using LSR II and
FACSDiva software (BD Biosciences). Data were analyzed using FlowJo soft-
ware (TreeStar, Ashland, OR). After removal of the duplicates using the
forward-scatter area versus forward-scatter height plot, autologous stimulator
cells were excluded by gating on the CFSE-negative cells. Next, CD4 and
CD8 cells were gated within viable CD3 lymphocytes and analyzed sepa-
rately for the production of cytokines. For each cytokine, we evaluated the
percentage of cytokine-producing cells among all gated T cells in sample one
(restimulated with antigen-pulsed PBMCs) and sample two (restimulated
with unpulsed PBMCs). For each cytokine, antigen-responsive T cells were
defined as present if the stimulation index was  2 (sample one divided by
sample two) and a clearly separate cytokine-producing population distin-
guishable from the nonproducing cells was present in sample one, as described
previously.30 The patient was defined as having antigen-responsive T cells for
the analyzed cytokine if these criteria were met either for CD8 or CD4 T
cells. The interpretation of fluorescence-activated cell sorting data and the
response evaluation were performed according to established criteria for in-
tracellular cytokine staining, as described previously.29 All experiments were
performed and analyzed centrally by one investigator (H.Z.). To ensure the
quality of samples and the functional capacity of T cells, the cytokine response
after stimulation by influenza matrix protein 1 and nucleocapsid protein (1
g/mL; PepMix; JPT Peptide Technologies) was assessed as for the tumor-
associated antigens. Only patients with detectable influenza-responsive T cells
were further analyzed. Assay reproducibility was assessed in 61 additional
independent experiments performed exclusively in patients participating in
this study. The initial result (detection of antigen-responsive T cells, yes or no)
was confirmed in 51 of these assays (84%).
Statistics
The presence of antigen-responsive T cells was analyzed separately for
NY-ESO-1, MAGE-3, Melan-A, and survivin. Additional prognostic factors
considered were age (dichotomized using the median of the distribution), sex,
AJCC M category (M1a or b v M1c), and systemic treatments applied before
and after blood draw. Therapies were aligned to the following categories:
treatment with anti-CTLA4 antibody, immunotherapy other than anti-
CTLA4 antibody, monochemotherapy, polychemotherapy, and biochemo-
therapy. Follow-up time was defined from the date when blood was drawn for
T-cell analysis to the date of last follow-up or death. Disease-specific survival
probabilities were calculated, and only deaths resulting from melanoma were
considered, whereas deaths resulting from other causes were regarded as
censored events. Estimates of cumulative survival probabilities according to
the Kaplan-Meier method were described together with 95% CIs and com-
pared using log-rank tests. Median survival times (MSTs) are presented. Mul-
tivariable Cox proportional hazards analyses were used to determine the
independent effect of prognostic factors. All variables were considered in
multivariable analysis. In the first model (model A), patients with missing
values of significant factors were excluded. In the second model (model B),
missing values were dummy coded to allow the inclusion of all patients. Both
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Fig 1. Survival of patients with unresectable stage IV disease according to the presence or absence of T cells responding to (A) NY-ESO-1, (B) Melan-A, (C) MAGE-3,
and (D) survivin peptides.
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models were established using backward and forward stepwise procedures.
Remaining nonsignificant factors were assessed for potential confounding
effects. Changes in the estimates of factors in a model by more than 5% were
regarded as indicative for confounding. Results of the Cox model were de-
scribed by means of hazard ratios (HRs) together with 95% CIs, and P values
were based on the Wald test. Throughout the analysis, P values .05 were
considered statistically significant. All analyses were carried out using SPSS
version 19 (SPSS, Chicago, IL).
RESULTS
Patients
PBMCs initially collected for biobanking purposes were re-
quested by the participating clinical centers according to the inclusion
criteria. One of 117 samples was excluded from further analysis be-
cause influenza-responsive functional T cells could not be detected.
The other 116 patients were assigned to three cohorts: 84 patients with
unresectable distant metastasis and clinical follow-up after T-cell anal-
ysis (cohort A), 18 tumor-free long-term survivors (cohort B), and 14
healthy controls (cohort C). In cohort A (67% male), the MST was 9.7
months. Median follow-up was 24 months for 19 patients who were
alive at the last follow-up and 6.5 months for 65 patients who died;
73.5% of patients were assigned to the M category M1c. Median age
was 55 years, with an interquartile range (IQR) of 45 to 67 years. The
18 tumor-free long-term survivors of cohort B (also 67% male) had a
median age of 56.5 years (IQR, 48 to 68 years). Healthy controls had a
median age of 45 years (IQR, 41 to 59 years), and 50% were men
(cohort C). No patient had received NY-ESO-1 or Melan-A vaccines
before blood draw for T-cell analysis.
T-Cell Analysis Correlates With Overall Survival
In univariate analysis of 84 cohort A patients, the presence of T
cells responding to either NY-ESO-1, Melan-A, or MAGE-3 was asso-
ciated with improved overall survival (Table 1; Fig 1; Appendix Table
A1, online only). The most significant difference in survival for patients
with responsive T cells versus those without was seen for NY-ESO-1
(P  .001), with Melan-A less significant at P  .011 and MAGE-3 at
P  .042, whereas the presence or absence of T cells responsive to
survivin peptides was not associated with survival in this analysis. The
MST of patients possessing T cells responding to NY-ESO-1 and/or
Melan-A was 21 months, compared with 6 months for all others (Fig
2A). The survival benefit was also evident when the analysis was
limited to the detection of IFN-–producing T cells (Fig 2B) and when
CD4 and CD8 T cells were analyzed separately (Appendix Fig A1,
online only). The individual frequencies of IFN-–producing cells
after stimulation with NY-ESO-1 and Melan-A for cohort A patients
are listed in Appendix Table A2 (online only). As expected, the M
category (Table 1) was also prognostic: the MST was 21 months for
patients with soft tissue or lung metastases and normal LDH (M1a/b),
whereas it was 8 months for those with other visceral metastases or
elevated LDH (M1c; P  .024). Multivariable Cox proportional haz-
ards analysis of 53 patients with complete data on all significant factors
(model A) showed that the presence of T cells targeting NY-ESO-1
(HR, 0.29; P  .001) or Melan-A (HR, 0.18; P  .001) were indepen-
dently associated with a survival benefit, whereas for the M category
and T cells responding to MAGE-3, no additional significant prognos-
tic impact was found (Table 2). Model B included patients with miss-
ing data. In agreement with model A, this analysis of 83 patients
confirmed the prognostic impact of NY-ESO-1– and Melan-A–
responsive T cells, whereas significant independent roles of the M
category and MAGE-3 were likewise not observed (Table 3). A com-
plete analysis of T-cell responses against all four antigens was per-
formed in 44 patients. There was a strong correlation between the
number of targeted antigens and survival. Patients with no response to
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Fig 2. (A) Patients with circulating T cells responding to Melan-A and/or
NY-ESO-1 by producing at least one of six cytokines have a median survival time
of 21 months, compared with 6 months for those who are negative for both. (B)
Impact of Melan-A– and/or NY-ESO-1–responding interferon-–positive T cells on
survival. (C) Survival according to the number of targeted antigens per patient.
Only patients with analysis of responses to all four antigens are considered.
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any antigen, a response to a single antigen, or responses to at least two of
the four antigens had an MST of 4, 6, or 24 months, respectively (Fig 2C).
No association between survival and the frequency of influenza-specific
IFN-–producing CD4/CD8T cells was observed (data not shown).
Antigen-Responsive T Cells in Long-Term Survivors
T cells responding to NY-ESO-1 and Melan-A peptides were
detectable in 50% and 47%, respectively, of long-term survivors in
cohort B. Such T cells were also found in a high proportion of cohort
A patients who survived  18 months after analysis. In contrast, only
22% or 23% of patients who died within 6 months after T-cell analysis
possessed detectable peripheral blood NY-ESO-1– or Melan-A–
specific T cells, respectively. This was similar to the background level in
healthy controls. MAGE-3–specific T cells were detectable in a high
proportion of healthy controls (cohort C) but were equally frequent in
patients of cohort A with the worst prognosis. Survivin-responsive T
cells were rare and were found in only 14% of long-term survivors (Fig
3). Five recurrences but no deaths were observed among 18 cohort B
patients after a median follow-up of 18 months. Interestingly, NY-
ESO-1–responsive T cells were detected in only one (20%) of five
patients who experienced relapse, in contrast to eight (62%) of 13
long-term survivors without recurrences thus far. Similarly, only one
(25%) of four long-term survivors who experienced relapse versus
seven (54%) of 13 long-term survivors who did not assessed for
Melan-A had responsive T cells. Appendix Tables A3 and A4 (online
only) list frequencies of antigen-responsive CD4 and CD8 T cells
according to cytokine response to antigen stimulation.
DISCUSSION
Functional circulating tumor antigen–reactive T cells were found to
have an important impact on survival of patients with advanced mel-
anoma in this study. Melan-A– and NY-ESO-1–reactive T cells con-
tributed independently to prognosis and predicted survival better
than the AJCC M category in patients with distant metastasis. More-
over, patients possessing T cells reactive to more than one antigen had
better survival than those with T cells reactive to fewer. This finding
further supports but does not prove the hypothesis that antigen-
specific T cells play a causative role in the control of tumor cells. To our
knowledge, this is the first report to associate spontaneously occurring
functional T-cell responses to survival in patients with melanoma. The
proportion of patients with an NY-ESO-1– or Melan-A–stimulated
T-cell response was likewise high in the cohort of tumor-free long-
term survivors, indicating a prognostic value independent of tumor
burden. MAGE-3–reactive T cells were frequently found in healthy
controls, and the proportion was lower in all analyzed melanoma
Table 2. Final Model A of Multivariable Cox Proportional Hazards Analysis
Factor
Patients
HR 95% CI PNo. %
%
Dead
M category .943
M1a or b 18 34.0 77.8 0.97 0.48 to 2.00
M1c 35 66.0 77.1 1
NY-ESO-1–responsive T cells .001
Present 23 43.4 60.9 0.29 0.14 to 0.61
Absent 30 56.6 90.0 1
Melan-A–responsive T cells < .001
Present 16 31.9 56.3 0.18 0.08 to 0.42
Absent 37 68.1 86.5 1
MAGE-3–responsive T cells .341
Present 33 62.3 69.7 0.73 0.39 to 1.39
Absent 20 37.7 90.0 1
NOTE. Bold font indicates statistical significance.
Abbreviation: HR, hazard ratio.
Model A included 53 patient cases (those with missing values were
excluded) and was adjusted for confounding effects of M category, presence
of MAGE-3–responsive T cells and anti-CTLA4 treatment after T-cell analysis.
Table 3. Final Model B of Multivariable Cox Proportional Hazards Analysis
Factor
Patients
HR 95% CI PNo. %
%
Dead
M category .064
M1a or b 22 26.5 68.2 0.56 0.31 to 1.04
M1c 61 73.5 82.0 1
NY-ESO-1–responsive T cells .002
Present 35 42.2 62.9 0.42 0.24 to 0.73
Absent 48 57.8 89.6 1
Melan-A–responsive T cells .002
Present 22 32.4 63.6 0.36 0.19 to 0.69
Absent 46 67.6 84.8 1
MAGE-3–responsive T cells .103
Present 37 59.7 73.0 0.62 0.35 to 1.10
Absent 25 40.3 92.0 1
NOTE. Bold font indicates statistical significance
Abbreviation: HR, hazard ratio.
Model B included 83 patient cases (one had missing information for M
category and was excluded; those with missing values were assigned their
own category per characteristic; missing value categories for Melan-A–
specific T cells n  15 and MAGE-3 specific T cells n  21 were included)
and was adjusted for confounding effects of M category and presence of
MAGE-3–responsive T cells.
Tumor-free M1c analyzed after > 24 months survival in stage IV (n = 18)
Patients with unresectable stage IV who survived > 18 months after analysis (n = 23)
Patients with unresectable stage IV who survived 6-18 months after analysis (n = 25)
Patients with unresectable stage IV who survived < 6 months after analysis (n = 27)
Healthy controls (n = 14)
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Fig 3. Proportion of patients with T cells responding to NY-ESO-1, Melan-A,
MAGE-3, and survivin in long-term survivors, patients with unresectable stage IV
disease with follow-up after T-cell assay, and healthy controls.
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cohorts, suggesting a disease-related decrease of responsiveness to this
antigen.TheMcategorywasstronglyassociatedwithprognosisaccording
to univariate analysis but did not remain independently significant when
tested in conjunction with NY-ESO-1– and Melan-A–responsive T cells
in any model of the multivariate analysis. Nevertheless, a strong trend
was found according to model B (P  .064), whereas model A negated
any independent impact of the M category on survival. These differ-
ences might have been caused by the small sample size and need to be
clarified in larger patient cohorts.
Biobanking efforts of different centers enabled us to include
samples from patients for whom clinical follow-up was already avail-
able. Antigen-reactive T cells, either occurring spontaneously or after
vaccination, have been investigated before, but their correlation with
survival remains inconclusive, and most studies have not assessed any
aspects of the actual functional integrity of the T cells.21,22,26,28,31
Previous analyses have focused on different tumor-associated antigens
and methods to analyze T cell status. Van Oijen et al28 used tetramer
staining to analyze spontaneously occurring T cells in 62 patients with
distant metastasis. Specific T cells were detected in 68% of patients, but
no correlation of any of these cells with survival was observed. It has
been reported that the majority of tumor antigen–specific T cells in the
blood of patients with melanoma are not able to lyse tumor cells or to
produce any cytokines.26 In contrast, here we analyzed functional
response by measuring cytokine production on antigenic stimulation.
To minimize the risk of underestimating the frequency of T cells in
principle capable of responding to melanoma-associated antigens, we
quantified production of six cytokines. Because of different and par-
tially opposing functions of these cytokines in adaptive immunity, we
also compared survival of cohort A patients based only on detection of
IFN-–releasing T cells, which confirmed the strong impact of these
functional T cells on survival. The frequency of tumor antigen–
reactive memory T cells in vivo is too low to be detected directly ex vivo
by intracellular cytokine staining. Therefore, we initially applied a
limited 12-day in vitro stimulation to ensure expansion of memory
and not naive T cells to a measurable extent. For stimulation, nested
overlapping 15-mer peptides, spanning entire protein antigens, were
used as stimuli, allowing us to include patients of any HLA type.
Furthermore, considering the increasing appreciation of the impor-
tance of T helper responses for tumor rejection over the last few
years,32,33 it is noteworthy that both CD8 as well as CD4 responses are
stimulated and analyzed simultaneously with this approach.34
The prognostic impact of spontaneously occurring memory T
cells responsive to NY-ESO-1 and Melan-A was not restricted to
patients with limited stage IV disease; 73.5% of cohort A patients
presented with visceral metastases other than lung and/or elevated
LDH. The analysis of their T-cell responses enabled us to identify
patients with a chance of long-term survival, even among those in the
M1c category.
Our work provides a rationale for refining vaccination and T-cell
transfer strategies by targeting Melan-A and NY-ESO-1. Poor clinical
responses in previous trials might be explained by tumor-induced
escape mechanisms like downregulation of HLA class I or recruitment
of regulatory T cells to metastatic sites. For upcoming specific immu-
notherapies, combinations with newly available agents targeting im-
mune escape mechanisms should therefore be considered.
This analysis might also serve as a rationale for investigating the
pretherapeutic detection of circulating T cells reactive to melanoma-
associated antigens as a predictive marker for outcome after ipili-
mumab.8 Although the mode of action of this agent is incompletely
understood, it breaks tolerance by blocking CTLA-4 and amplifies
preexistent memory immune responses, which might be detectable by
our assay. Recent data implicate an association between outcome after
ipilimumab treatment and the existence of post-treatment T-cell re-
sponses targeting NY-ESO-1.35,36
In conclusion, circulating functional T cells targeting melanoma-
associated antigens in patients with melanoma with distant metastasis
have strong prognostic impact. T cells responding to Melan-A pep-
tides (HR, 0.18; P  .001) or NY-ESO-1 peptides (HR, 0.29; P  .001)
were independently associated with a survival benefit and superior to
the M category in predicting outcome according to Cox regression
analysis. In addition, our findings provide a rationale for pursuing
vaccination and T-cell transfer strategies targeting Melan-A and NY-
ESO-1.
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Appendix
Table A1. Two- and 3-Year Survival According to Kaplan-Meier Method
Factor No. % % Dead
2-Year Survival Rate 3-Year Survival Rate
P% 95% CI % 95% CI
Age, years .755
 55 41 48.8 73.2 29.5 14.8 to 44.2 21.1 6.8 to 35.4
 55 43 51.2 81.4 29.7 15.0 to 44.4 20.8 7.5 to 34.1
Sex .715
Male 56 66.7 75.0 27.0 14.1 to 39.9 20.2 7.7 to 32.7
Female 28 33.3 82.1 33.8 16.0 to 51.6 22.6 6.7 to 38.5
M category .024
M1a or b 22 26.5 68.2 48.1 26.5 to 69.7 42.1 20.1 to 64.1
M1c 61 73.5 82.0 20.9 9.7 to 32.1 11.6 2.4 to 20.8
NY-ESO-1–responsive T cells  .001
Present 36 42.9 61.1 48.6 31.0 to 66.2 36.4 18.6 to 54.2
Absent 48 57.1 89.6 15.3 4.5 to 26.1 9.6 0.4 to 18.8
Melan-A–responsive T cells .011
Present 22 31.9 63.6 53.7 32.5 to 74.9 47.0 24.7 to 69.3
Absent 47 68.1 83.0 21.3 8.8 to 33.8 10.9 0.3 to 21.5
MAGE-3–responsive T cells .042
Present 38 60.3 71.1 32.1 16.0 to 48.2 28.1 12.2 to 44.0
Absent 25 39.7 92.0 16.0 1.7 to 30.3 12.0 0.0 to 24.7
Survivin-responsive T cells .374
Present 8 15.1 62.5 43.7 6.9 to 80.5 43.7 6.9 to 80.5
Absent 45 84.9 80.0 26.2 12.7 to 39.7 20.4 7.7 to 33.1
Prior systemic treatments
Anti-CTLA-4 .218
Yes 9 10.7 44.4 32.4 0.0 to 80.2 32.4 0.0 to 80.2
No 75 89.3 81.3 28.0 17.4 to 38.6 19.4 9.8 to 29.0
Other immunotherapy .260
Yes 39 46.4 74.4 34.5 18.6 to 50.4 31.0 15.3 to 46.7
No 45 53.6 80.0 25.3 11.6 to 39.0 11.4 0.2 to 22.6
Monochemotherapy .505
Yes 22 26.2 72.7 27.1 4.8 to 49.4 18.1 0.0 to 38.9
No 62 73.8 79.0 30.2 18.4 to 42.0 21.8 10.6 to 33.0
Polychemotherapy .802
Yes 7 8.3 71.4 0.0 0.0 to 0.0 0.0 0.0 to 0.0
No 77 91.7 77.9 30.8 20.0 to 41.6 21.9 11.7 to 32.1
Biochemotherapy .447
Yes 7 8.3 57.1 53.6 14.2 to 93.0 26.8 0.0 to 68.7
No 77 91.7 79.2 27.6 17.0 to 38.2 20.4 10.4 to 30.4
Subsequent systemic treatments
Anti-CTLA-4 .421
Yes 18 21.4 61.1 32.7 5.5 to 59.9 0.0 0.0 to 0.0
No 66 78.6 81.8 28.1 16.9 to 39.3 21.1 10.7 to 31.5
Other immunotherapy .656
Yes 17 20.2 88.2 29.4 7.6 to 51.2 15.7 0.0 to 34.1
No 67 79.8 74.6 29.9 17.9 to 41.9 23.0 11.6 to 34.4
Monochemotherapy .171
Yes 36 42.9 86.1 25.4 10.7 to 40.1 9.1 0.0 to 20.3
No 48 57.1 70.8 32.4 17.9 to 46.9 29.5 15.2 to 43.8
Polychemotherapy .164
Yes 19 22.6 89.5 17.5 0.0 to 35.3 11.7 0.0 to 26.8
No 65 77.4 73.8 33.3 21.1 to 45.5 24.4 12.6 to 36.2
Biochemotherapy .713
Yes 12 14.3 91.7 33.3 6.6 to 60.0 11.1 0.0 to 30.9
No 72 85.7 75.0 29.7 18.3 to 41.1 23.6 12.6 to 34.6
P values are results of log-rank tests excluding patient cases with missing values.
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Table A2. Frequencies of IFN-–Positive T Cells in 84 Cohort A Patients After Stimulation With NY-ESO-1 or Melan-A Peptides and in Unstimulated Controls
Patient No.
NY-ESO-1
Stimulated (%)
Melan-A
Stimulated (%)
Unstimulated
Control (%)
Patient No.
NY-ESO-1
Stimulated (%)
Melan-A
Stimulated (%)
Unstimulated
Control (%)
CD4 CD8 CD4 CD8 CD4 CD8 CD4 CD8 CD4 CD8 CD4 CD8
1 0.06 0.10 0.03 0.09 0.03 0.04 43 0.03 0.08 0.11 5.85 0.03 0.07
2 6.20 2.25 3.61 32.34 2.56 1.42 44 0.26 0.59 ND ND 0.72 0.41
3 0.88 0.01 0.48 0.01 0.40 0.03 45 0.35 0.68 0.64 1.27 0.54 0.64
4 0.96 5.52 0.60 1.75 0.64 1.04 46 0.19 0.39 0.19 0.49 0.13 0.71
5 2.22 0.09 2.35 0.04 2.43 0.04 47 0.30 0.05 0.25 0.06 0.28 0.02
6 0.19 0.29 ND ND 0.11 0.29 48 0.02 0.04 0.03 0.05 0.02 0.02
7 0.17 0.02 0.18 0.00 0.16 0.01 49 0.66 0.02 0.55 0.07 0.54 0.06
8 0.64 0.92 0.37 1.05 0.70 3.68 50 0.15 0.32 0.19 0.74 0.18 0.73
9 0.01 0.02 0.01 0.07 0.01 0.02 51 0.78 0.07 0.80 0.23 1.00 0.08
10 0.10 0.03 0.11 0.27 0.06 0.07 52 0.22 0.27 ND ND 0.24 0.24
11 2.60 0.22 ND ND 0.62 0.21 53 0.40 0.02 0.39 0.02 0.42 0.01
12 0.07 0.06 ND ND 0.04 0.06 54 4.53 0.78 4.55 0.51 5.19 0.40
13 0.06 0.29 0.07 0.37 0.04 0.24 55 3.50 0.89 3.79 1.65 3.46 1.11
14 4.68 0.90 1.65 0.67 1.05 0.65 56 1.42 0.03 0.91 0.03 0.87 0.02
15 0.61 0.70 0.56 2.73 0.55 0.72 57 0.06 0.09 ND ND 0.02 0.06
16 0.01 0.06 ND ND 0.01 0.03 58 2.72 0.22 2.77 0.15 2.33 0.14
17 6.54 5.16 6.17 5.68 5.31 4.65 59 0.02 0.01 ND ND 0.01 0.01
18 2.73 1.50 0.63 0.93 0.48 0.19 60 0.29 0.05 0.48 0.07 0.47 0.02
19 ND ND ND ND ND ND 61 0.18 0.08 0.07 0.06 0.08 0.08
20 0.01 0.11 0.75 0.48 0.01 0.01 62 0.14 0.09 0.08 0.07 0.15 0.10
21 0.43 0.24 0.44 0.20 0.44 0.12 63 0.57 0.39 0.55 0.45 0.48 0.30
22 0.62 0.10 0.38 0.53 0.25 0.08 64 0.04 0.34 ND ND 0.02 0.34
23 2.21 0.84 1.22 1.17 1.68 0.49 65 0.02 0.08 ND ND 0.03 0.12
24 2.80 0.59 3.08 6.29 2.49 0.69 66 0.01 0.16 0.01 0.38 0.01 0.27
25 3.51 1.55 ND ND 3.87 0.12 67 0.69 1.69 0.18 1.10 0.36 1.92
26 0.08 0.07 0.08 0.08 0.09 0.10 68 0.12 0.09 0.02 0.07 0.04 0.14
27 0.24 0.06 ND ND 0.06 0.06 69 0.28 0.12 0.28 0.17 0.52 0.10
28 0.29 0.09 0.58 0.04 0.25 0.07 70 0.22 0.04 0.10 0.59 0.07 0.04
29 1.52 0.06 0.67 0.11 0.65 0.06 71 0.02 0.11 0.01 0.14 0.01 0.13
30 6.54 0.26 7.69 0.29 7.64 0.14 72 0.39 1.00 0.41 0.09 0.38 0.13
31 0.06 0.16 0.05 0.13 0.07 0.16 73 1.06 0.17 0.50 0.27 0.42 0.18
32 0.88 0.08 ND ND 1.10 0.04 74 0.29 0.10 0.30 0.20 0.29 0.15
33 0.37 0.04 0.33 0.05 0.34 0.06 75 0.36 0.36 0.23 0.39 0.21 0.20
34 0.46 0.11 0.42 0.10 0.62 0.18 76 0.93 0.25 0.76 2.58 0.73 0.10
35 0.92 0.48 0.83 0.70 0.67 0.42 77 0.83 3.16 0.27 0.18 0.03 0.01
36 0.42 0.39 0.34 0.32 0.32 0.25 78 0.12 0.04 ND ND 0.02 0.01
37 0.13 0.45 ND ND 0.07 0.59 79 0.51 0.36 0.33 0.22 0.40 0.37
38 1.91 12.59 ND ND 0.98 0.54 80 0.01 0.05 0.01 0.06 0.01 0.06
39 0.80 0.23 0.69 0.18 0.64 0.16 81 0.28 1.02 2.90 2.26 0.10 0.16
40 0.03 0.04 0.04 0.08 0.03 0.07 82 0.53 3.00 0.15 1.42 0.10 0.02
41 0.36 0.43 0.43 0.33 0.28 0.24 83 0.22 0.01 0.07 0.03 0.06 0.03
42 0.39 0.17 0.19 0.41 0.08 0.31 84 0.19 0.11 0.08 0.07 0.07 0.05
Abbreviations: IFN-, interferon-gamma; ND, not done.
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Table A3. Frequencies of Antigen-Responsive CD4 T Cells According to Six Cytokines and Five Antigens
Responsive T Cells Detectable
Mean Frequency  Standard Deviation (%)
CD4IFN CD4IL-10 CD4IL-17 CD4IL-2 CD4IL-4 CD4TNF-
NY-ESO-1
No
Control 0.52  1.10 0.06  0.07 0.08  0.33 0.18  0.38 0.06  0.18 1.48  2.37
Stimulated 0.56  1.04 0.07  0.08 0.12  0.38 0.28  0.45 0.08  0.16 2.10  2.71
Yes
Control 0.66  1.23 0.14  0.16 0.11  0.15 0.17  0.17 0.10  0.14 2.22  3.69
Stimulated 1.69  3.14 0.13  0.17 0.17  0.30 0.46  0.96 0.16  0.23 4.12  5.85
Melan-A
No
Control 0.61  1.23 0.08  0.09 0.13  0.34 0.20  0.21 0.08  0.18 2.01  2.43
Stimulated 0.67  1.31 0.07  0.08 0.15  0.33 0.22  0.23 0.11  0.25 2.21  2.69
Yes
Control 0.51  1.03 0.07  0.07 0.07  0.13 0.22  0.49 0.09  0.17 2.09  3.12
Stimulated 1.31  1.03 0.07  0.07 0.08  0.11 0.24  0.49 0.24  1.20 2.49  3.04
MAGE-3
No
Control 0.60  0.89 0.08  0.12 0.09  0.15 0.14  0.13 0.05  0.06 1.79  2.37
Stimulated 0.56  0.81 0.08  0.10 0.09  0.16 0.19  0.21 0.05  0.05 1.89  2.77
Yes
Control 0.62  1.37 0.06  0.07 0.13  0.36 0.24  0.40 0.10  0.22 2.12  2.89
Stimulated 1.56  3.16 0.07  0.07 0.21  0.53 0.38  0.56 0.21  0.55 3.93  5.90
Survivin
No
Control 0.66  1.19 0.08  0.11 0.13  0.34 0.23  0.37 0.07  0.19 2.38  3.07
Stimulated 0.71  1.33 0.09  0.12 0.15  0.37 0.27  0.41 0.10  0.30 2.57  3.16
Yes
Control 0.77  1.44 0.13  0.18 0.12  0.10 0.17  0.16 0.12  0.20 3.50  4.67
Stimulated 0.95  1.28 0.08  0.08 0.12  0.11 0.25  0.20 0.26  0.73 4.34  4.25
Influenza
Yes
Control 0.86  2.08 0.15  0.29 0.10  0.34 0.24  0.44 0.07  0.12 2.44  3.42
Stimulated 8.87  10.40 0.12  0.21 0.21  0.60 1.13  1.64 0.71  4.19 13.26  12.72
Abbreviations: IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
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Table A4. Frequencies of Antigen-Responsive CD8 T Cells According to Six Cytokines and Five Antigens
Responsive T Cells Detectable
Mean Frequency  Standard Deviation (%)
CD8IFN- CD8IL-10 CD8IL-17 CD8IL-2 CD8IL-4 CD8TNF-
NY-ESO-1
No
Control 0.16  0.32 0.09  0.15 0.06  0.11 0.08  0.11 0.06  0.10 0.79  1.30
Stimulated 0.19  0.28 0.10  0.16 0.08  0.08 0.12  0.13 0.10  0.13 0.93  1.25
Yes
Control 0.36  0.86 0.12  0.11 0.16  0.24 0.11  0.10 0.15  0.20 0.99  1.16
Stimulated 1.25  2.96 0.12  0.12 0.20  0.25 0.13  0.10 0.22  0.30 2.28  3.76
Melan-A
No
Control 0.33  0.76 0.11  0.16 0.11  0.19 0.11  0.09 0.09  0.13 1.08  1.30
Stimulated 0.35  0.77 0.11  0.21 0.20  0.66 0.12  0.11 0.20  0.64 1.15  1.52
Yes
Control 0.14  0.19 0.09  0.09 0.10  0.20 0.10  0.12 0.13  0.22 0.95  1.33
Stimulated 0.96  1.69 0.11  0.11 0.14  0.27 0.14  0.17 0.63  2.44 2.31  3.12
MAGE-3
No
Control 0.35  0.72 0.11  0.16 0.11  0.21 0.09  0.11 0.11  0.13 0.92  1.54
Stimulated 0.31  0.52 0.11  0.21 0.07  0.08 0.11  0.16 0.10  0.07 0.86  1.52
Yes
Control 0.21  0.61 0.07  0.09 0.10  0.19 0.11  0.11 0.11  0.18 0.87  0.98
Stimulated 2.09  7.57 0.08  0.09 0.17  0.38 0.12  0.14 0.27  0.67 3.98  11.78
Survivin
No
Control 0.19  0.28 0.09  0.12 0.10  0.18 0.09  0.11 0.09  0.16 0.98  1.28
Stimulated 0.24  0.37 0.11  0.19 0.16  0.65 0.11  0.15 0.15  0.63 1.05  1.48
Yes
Control 0.51  1.02 0.09  0.10 0.22  0.32 0.10  0.07 0.17  0.25 1.69  1.63
Stimulated 0.28  0.29 0.08  0.05 0.09  0.05 0.13  0.10 0.32  0.80 1.64  1.96
Influenza
Yes
Control 0.38  1.07 0.50  1.29 0.13  0.19 0.18  0.39 0.14  0.19 1.28  2.52
Stimulated 12.98  19.31 0.30  0.61 0.17  0.27 0.24  0.30 0.55  4.21 14.99  20.11
Abbreviations: IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
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Fig A1. More favorable survival curves for patients with (A) CD8 T cells and (B) CD4 T cells responding to Melan-A or NY-ESO-1 when analyzed separately.
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GLOSSARY TERMS
AJCC/UICC-TNM staging: The TNM Classification of Ma-
lignant Tumours (TNM) is a cancer staging system that describes the
extent of cancer in a patient’s body. T describes the size of the tumor and
whether it has invaded nearby tissue; N describes regional lymph nodes
that are involved; M describes distant metastasis (spread of cancer from
one body part to another). TNM is developed and maintained by the
International Union Against Cancer (UICC) to achieve consensus on
one globally recognized standard for classifying the extent of spread of
cancer. The TNM classification is also used by the American Joint Com-
mittee on Cancer (AJCC). In 1987, the UICC and AJCC staging systems
were unified into a single staging system. Prognosis of a patient is de-
fined by the TNM classification.
Cox regression analysis: The Cox proportional hazards regres-
sion model is a statistical model for regression analysis of censored sur-
vival data. It examines the relationship of censored survival distribution
to one or more covariates. It produces a baseline survival curve, covari-
ate coefficient estimates with their standard errors, risk ratios, 95% CIs,
and significance levels.
MAGE-3: Protein encoded by the MAGE A locus. MAGE
genes are normally silent in normal tissues but expressed in
several cancers.
Melan-A: A melanoma-related antigen. MART-1 is absent in
all normal cells except for melanocytes and the retina. In addition, apart
from melanomas, MART-1 has not been observed in any other cancers.
Consequently, the MART-1 antigen is considered to have a melanoctye
lineage.
NY-ESO-1: Also known as CTAG1B or cancer/testis antigen 1B, the
gene codes for antigens recognized on neoplastically transformed
T cells.
Survivin: IAPs suppress host cell death in response to viral infection.
By binding to caspases, they directly inhibit apoptosis. Survivin and
xIAP are members of this family, differing perhaps in binding to selec-
tive caspases. BIRC5: Tumor-associated protein belonging to the group
of shared overexpressed antigens.
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Abstract 
Clinical trials of vaccines and immunomodulators are yielding impressive results, but still only in a 
minority of melanoma patients. Patient parameters associated with successful therapy are largely 
undefined, and whether targeting particular antigens can result in a better clinical outcome than others 
is not clear. Furthermore, predictive markers are mostly lacking. Initially, we observed in a cohort of 
late-stage melanoma patients that the presence of NY-ESO-1- and/or Melan-A-reactive T cells in the 
peripheral blood was significantly associated with prolonged survival. Here we report on the 
phenotypes and functions of these T cell antigen responses and their prognostic impact. We assayed 
functional antigen-reactive T cells with an intracellular cytokine staining protocol using multicolor flow 
cytometry to detect six cytokines simultaneously, allowing us to analyze the cell type (CD4+ or CD8+) 
and the released cytokines at the single-cell level. We observed that NY-ESO-1 was generally 
recognized more frequently by CD4+ than by CD8+ T cells under  these conditions, both being 
associated with a positive effect on patient survival. In contrast, Melan-A mainly stimulated CD8+ T 
cells and additional or sole recognition by CD4+ T cells was associated with a poor clinical outcome. 
We also observed distinct cytokine profile differences between NY-ESO-1- and Melan-A-reactive T 
cells and between CD4 and CD8 responses. Pro-inflammatory responses seemed to be favourable for 
both antigens, but especially for Melan-A. Taken together, our data support NY-ESO-1 and Melan-A 
as target antigens of choice for melanoma immunotherapy. The finding that CD4+T cell recognition of 
Melan-A had a strong negative correlation with survival should be considered for upcoming trials 
attempting to stimulate both CD4- and CD8-mediated responses to this antigen. 
 
Introduction 
The annual increase of malignant melanoma lies between 3 and 7% per year and trends suggest that 
the incidence per year will even double within the next 10 to 20 years (1, 2). Once a patient has failed 
surgery, conventional treatments like chemo- and radiotherapy remain the first choice despite poor 
clinical efficacy resulting in a very poor prognosis (3, 4). Due to this modest success rate, other 
treatments are clearly necessary, and immunotherapy is increasingly being applied for melanoma 
management (in detail reviewed by Zeiser et al. (5)). Clinical approaches in melanoma immunotherapy 
commonly include attempts to generate either in vivo or in vitro a sufficient amount of activated anti-
tumor T cells specific for tumor-associated antigens (TAAs) expressed by that individual patient´s 
tumor. Furthermore, these T cells must be in a position to circumvent tumors’ immune escape 
mechanisms. There are many ways to address the above issues, but so far the results of melanoma 
immunotherapy have been generally rather disappointing. Nonetheless, several recent reports of 
immune treatments leading to impressive clinical responses are raising optimism in the field. In 2010, 
a randomized double blind placebo-controlled phase 3 trial of Ipilimumab, an anti-CTLA-4 antibody, 
resulted in a statistically significant survival benefit in stage IV advanced melanoma patients (6). 
These clinical benefits, including shrinkage or complete disappearance of large tumor masses, are 
often associated with the demonstrable presence of CD8+, antigen-specific T cells in peripheral blood 
(7). In a different approach, impressive clinical responses after adoptive transfer of TAA-specific T 
cells clearly reveal the importance of these cells for successful therapy (8). More recently, in a phase 1 
study, different cancer patients were treated with an anti-PD-1 antibody resulted in objective 
responses (complete or partial responses) in about 20% of all treated patients (9). Furthermore, 
accumulating data suggest that even conventional anti-cancer treatments like chemotherapy or non-
specific systemic immunotherapy (such as application of cytokines) depend for their long-term success 
at least partly on the generation of tumor-antigen-specific T-cells capable of maintaining anti-tumor 
immune responses (10, 11). 
In this light, and given that only a fraction of patients responds well to each therapeutic modality, 
predictive markers for clinically efficient immunological treatments are required. Currently, only the 
amount of plasma Lactate dehydrogenase (LDH) is an established biomarker in malignant melanoma 
(12) and although several other serum markers have been investigated for their prognostic power (13, 
14), none is widely accepted so far. It might be of great relevance to undertake functional testing of 
each patient´s anti-tumor repertoire prior to initiating therapy. Using PBMC and in vitro stimulation with 
tumor antigens, an integrated readout of the presence of, and nature of, potential anti-tumor activity 
may be valuable. In a previous study in a large cohort of stage IV melanoma patients, we showed that 
the presence in the peripheral blood of T cells responding to the cancer/testis antigen NY-ESO-1 or 
the well-studied differentiation antigen Melan-A had a strong independent prognostic impact on 
survival. Multivariate analyses showed that patients possessing T cells responding to NY-ESO-1 
(NYE) or Melan-A (Melan) had a clear survival benefit compared to patients without these T-cells (15). 
Here, we analyzed in detail the importance of the nature of the T cell response, whether CD4+ and/or 
CD8+ T cell-mediated, and the balance of the production of 6 pro- and anti-inflammatory cytokines at 
the individual cell level.  
 
Patients and Methods 
Patients 
47 patients with Melan-A and/or NY-ESO-responsive T cells, which were part of an already published 
report (15), were included here. Briefly, blood cells were collected from four different centers in 
Europe: Tübingen, Essen (both Germany), Nijmegen (Netherlands) and Siena (Italy). Only stage IV 
Melanoma patients with unresectable distant metastases at the time of blood draw and available 
survival follow up data were included. All patients had given their written informed consent for 
biobanking. The conduct of this study was approved by the Ethics Committee, Tübingen (approvals 
147/2011BO2 and 432/2011BO2). All experiments were performed and analyzed centrally by one 
operator (H.Z.). 
Intracellular cytokine assay 
CD4 and CD8 T-cell responses against NYE and Melan were measured as described previously (15). 
Briefly, after thawing, cells were stimulated with protein-spanning overlapping peptides (1 µg/mL; 
PepMix™; JPT Peptide Technologies, Berlin, Germany), representing each of the two antigens. 
Additionally, cells were also stimulated with overlapping peptides representing the Influenza A-derived 
molecules Nucleocapsid protein and Matrix protein 1. These responses served as positive controls, 
because all patients had been exposed to influenza during their lives. After 12 days culture to amplify 
the memory cell response, antigen-reactive T-cells were restimulated in the presence of Golgi-Plug (1 
µL/mL; BD Bioscience, Ontario, Canada) with autologous antigen-pulsed PBMCs (at a ratio of 1:2) 
that were previously stained with CFSE (5 µM; Invitrogen, Karlsruhe, Germany). Unpulsed PBMCs 
were used as a negative control. After 12 h restimulation, assay readout was intracellular staining for 6 
different cytokines simultaneously allowing an analysis of the T cell phenotype and effector functions 
(pro- versus anti-inflammatory response) on a single-cell basis. The following antibodies were used: 
CD3 – Qdot655 (Invitrogen), anti-CD4 + Pacific Orange (Invitrogen), CD8 – APC-H7 (BD Bioscience), 
IFN-γ – PE-Cy7 (BD Bioscience), TNF-PE (Miltenyi Biotec, Bergisch Gladbach, Germany), IL-2 – 
Alexa700 (BioLegend, San Diego, USA), IL-4 – APC (BD Bioscience), IL-10 – Pacific Blue 
(eBioscience, San Diego, USA) and IL-17 – PerCP-Cy5.5 (eBioscience). Flow Cytometry data were 
obtained using a 14-colour BD LSR II (BD Bioscience) together with the FACSDiva software (BD 
Bioscience). 
Gating strategy 
Data were analyzed using FlowJo software (Tree Star Inc, Ashland, USA). After removal of the 
doublets using the FSC-Area plotted versus the FSC-Height, restimulators were excluded by gating on 
the CFSE-negative cells. After that, CD4+ and CD8+ cells were gated within viable (EMA-negative), 
CD3+ lymphocytes. Subsequently, both the CD4+ and the CD8+ fraction were analyzed for the 
production of the 6 cytokines. 
For the definition of a positive response, established criteria were used as previously described. A 
response was defined as positive if the percentage of cytokine-producing cells within all CD4+ or 
CD8+ T-cells of the sample restimulated with loaded APCs was at least twice that of controls 
incubated with unpulsed autologous APCs. Further, the dot plots of each positive response were again 
reviewed and only clearly separate cytokine-positive populations were finally defined as significant. 
Simultaneously measured responses against Influenza served as a positive control. Only patients that 
possessed a response against the Influenza-derived peptides were included in the analyses. Finally, 
the production of IL-4 and/or IL-10 was defined as anti-inflammatory response, whereas a detection of 
IFN-γ, TNF, IL-2 and/or IL-17 was classified as a pro-inflammatory response. 
 
 
Statistics 
The presence or absence of antigen-responsive T cells was analyzed separately for NYE, Melan and 
Influenza (Flu). CD4 and CD8 responses were analysed separately. If more than one cytokine could 
be detected, responses were defined as being polyfunctional (in comparison to monofunctional 
responses). Follow-up time was defined from the date when blood was drawn for T cell analysis to the 
date of last follow-up or death. Disease-specific survival probabilities have been calculated and only 
deaths due to melanoma have been considered, whereas deaths due to other causes were regarded 
as censored events. Estimates of cumulative survival probabilities according to Kaplan-Meier were 
described and compared using Log rank tests. Throughout the analysis, P<0.05 was considered as 
statistically significant. All statistical analyses were performed using GraphPad Prism version 5.04 for 
Windows (GraphPad Software, San Diego California USA). 
 
  
Results 
Patients 
PBMCs that were initially collected for biobanking purposes were provided by the participating clinical 
centers. 47 patients with unresectable distant metastasis and clinical follow-up after blood draw could 
finally be included into the cohort. 22 patients had Melan-A and 36 patients had NY-ESO-1-reactive T 
cells. 11 patients had both. 64% of the patients were male and the median survival time of the whole 
cohort was 650 days. Median follow-up was 1286 days for 14 patients who were alive at the last 
follow-up and 338 days for 33 patients who died; 61.7% of patients were assigned to the M category 
M1c. Median age was 55 years, with an interquartile range (IQR) of 45 to 67 years. No patient had 
received NYE or Melan vaccines before blood draw for T-cell analysis. 
22 patients had detectable Melan-A- and 36 NY-ESO-1-reactive T cells, including 11 patients who had 
both. Median survival time was 650 days for patients with NYE-reactive T cells (1-year survival rate 
63.33%) and 679 days for patients responding to Melan-A (1-year survival rate 59.01%) 
NY-ESO-1 
Figure 1A shows the proportion of patients with CD4+ and/or CD8+ T cells responding to each 
antigen. For NY-ESO-1, 23 of 36 patients (64%) had only CD4+ NYE-reactive T cells, 3 of 36 patients 
(8%) had solely CD8+ T cells and 10 patients (28%) had both cell types responding to the antigen. 
When stimulated with NY-ESO-1, regarding both CD4 and CD8 driven responses, we mainly detected 
the pro-inflammatory cytokines IFN-γ (25 of 36 patients; 69%) and TNF (23 of 36 patients; 64%). IL-2 
could be detected in 17 of 36 patients (47%) responding to NY-ESO-1, whereas IL-4 (7 patients; 19%), 
IL-17 (6 patients; 17%) and IL-10 (1 patient; 3%) were only infrequently released. In total, NY-ESO-1 
stimulation resulted in the release of anti-inflammatory cytokines (IL-4 and IL-10) in 8 patients (22%) 
(Figure 2A). 
Each antigen was preferentially detected by either CD4+ or CD8+ T cells (Figure 1). Therefore,, we 
next analyzed the CD4+ and CD8+ T cell responses separately for cytokine production (Figure 3A). 
Patients with NY-ESO-1-responsive CD4+ T cells produced mainly IFN-γ (21 of 36 patients; 58%), 
TNF (16 patients; 44%) and IL-2 (15 patients; 42%). IL-4 (7 patients; 19%) and IL-17 (6 patients; 17%) 
were only detected in a few patients. IL-10 could not be detected. Concerning the cytokine production 
patterns of CD8+ NY-ESO-1-reactive T cells we interestingly observed that TNF (10 of 36 patients; 
28%) was the most frequently released cytokine, followed by IFN-γ (9 patients; 25%). IL-2 (2 patients; 
6%), IL-4 (2 patients; 6%) and IL-10 (1 patient; 3%) were only occasionally detected. IL-17 was not 
detected. 
We additionally investigated, whether the patients’ antigen-specific T cells produced only one (single) 
or more cytokines (multiple cytokine response) in response to antigen (Figure 4). Concerning NY-
ESO-1, we observed that stimulation with this antigen, led mainly to the release of multiple cytokines 
in the CD4 compartment (21 patients; 58%). Only 12 patients with CD4+ NY-ESO-1-reactive T cells 
responded upon stimulation with one single cytokine (33%). In the CD8 compartment, single cytokine 
responses were also only infrequently detected (4 patients; 11%). In 9 patients (25%), multiple 
cytokines were detected upon stimulation. 
Finally, we stratified the patients according the presence or absence of the above-analyzed 
phentotypic or functional parameters, separately for the CD4 and CD8 compartment. A detailed 
overview of the univariate analyses is presented in Table 1A for NY-ESO-1 and 1B for Melan-A. 
Phenotypically, NY-ESO-1 was mainly recognized by CD4+ T cells. However, there was no correlation 
between the presence of CD4+ or CD8+ reactive T cells, or both, and survival. Any NY-ESO-1 
reactivity was equally associated with better survival. Functionally, NY-ESO-1-reactive T cells were 
found to produce mainly pro-inflammatory cytokines upon antigen restimulation. We distinguished 
between “unopposed pro-inflammatory” (only release of IFN-γ, TNF, IL-2 and/or IL-17) and those 
responses where anti-inflammatory cytokines (IL-4 and IL-10) were also present or only present (pure 
anti-inflammatory and mixed responses). Kaplan-Meier analyses revealed that neither pro- versus 
anti-inflammatory nor mono- versus polyfunctional responses had an impact for patients with T cells 
responding to NYE (for both CD4 and CD8 responses). 
Melan-A 
In contrast to NY-ESO-1 reactivity, most of the patients with measurable Melan-A responses, had only 
T cells restricted to the CD8 phenotype (13 of 22 patients, 59%). Only 3 of these 22 patients (14%) 
had solely CD4+ T cells responding to Melan-A, 6 patients showed both, CD4 and CD8 responses 
(27%) (Figure 1B). 
Similar to NY-ESO-1, Melan-A-reactive T cells mainly released IFN-γ (14 of 22 patients; 64%) and 
TNF (11 patients; 50%). However, IL-2 was detected in only 2 patients (9%). IL-17 (3 patients; 14%), 
IL-4 (3 patients; 14%) and IL-10 (3 patients; 14%); were detected in equally low frequencies to NY-
ESO-1 stimulated cells (Figure 2B). In total, anti-inflammatory cytokines could be detected in 27% of 
all patients with Melan-A-specific T cells (6 patients). 
When we analyzed the CD4 compartment separately from the CD8 cells, we observed that IFN-γ was 
only detected in a few patients (2 of 22 patients; 9%). TNF (5 of 22 patients; 9%) and even IL-17 (3 
patients; 14%) and IL-4 (3 patients; 14%) were detected more frequently. IL-2 and IL-10 could not be 
detected at all. CD8+ Melan-A-reactive T cells mainly produced IFN- γ (14 patients; 64%) and TNF (8 
patients; 36%). IL-10 (3 patients; 14%), IL-2 (2 patients; 9%), IL-17 (1 patient; 5%) and IL-4 (1 patient; 
5%) detection was rare (Figure 3B). 
In contrast to all NY-ESO-1-driven responses, differences in single versus multiple cytokine responses 
were more balanced concerning Melan-A-reactivity. CD4+ Melan-A-reactive T cells released more 
frequently one single cytokine (5 patients; 23% versus 4 patients; 18% with multiple cytokine 
responses) whereas CD8+ Melan-A-reactive T cells released again mainly multiple cytokines (10 
patients; 45% versus 9 patients; 41% with single cytokine responses) (Figure 4). 
In contrast to the NY-ESO-1 data, Melan-A stimulated mainly CD8+ T-cells. Kaplan-Meier analysis 
revealed that neither a Melan-A response limited to CD8+ T cells (P=0.0951) or a mixed response of 
both CD4 and CD8 cells (P=0.8711) were associated with better survival, but the presence of 
responses limited to CD4+ cells were strongly associated with poor survival (Figure 4A; P=0.0040). 
These patients had a median survival time of 112 days, compared to 824 days for the remaining 
patients with Melan-reactive T cells (Hazard ratio = 36.67). In fact, there was a tendency for patients 
with CD4+ reactive cells to do worse even than those without any Melan-reactive cells. 
In contrast, strikingly, the inflammatory nature of the CD4+ response after Melan stimulation had a 
significant impact on survival (Figure 4B; P = 0.0046). Patients whose CD4+ T cells responded to 
Melan stimulation with the production of anti-inflammatory cytokines had a MST of only 83 days. 
Patients that did not release IL-4 and/or IL-10 had a MST of 1976 days (Hazard ratio = 0.05). Mono- or 
polyfunctional responses did not have an impact for patients with T cells responding to Melan (CD4 
and CD8).  
Influenza 
In all 47 patients, influenza antigens were recognized by both CD4+ and CD8+ T cells at the same 
time. Interestingly, IFN-γ was detected in every sample (100%). TNF (46 patients; 98%) and IL-2 (41 
patients; 87%) responses were more frequent, IL-17 (22 patients; 47%), IL-4 (23 patients; 49%) and 
IL-10 (3 patients; 6%) only rarely detected. 
 
  
Discussion 
There are a number of immunotherapeutic approaches emerging that clearly show clinical efficacy, 
even in advanced melanoma patients. Early studies of interleukin 2 treatments with long-term follow-
up documented that immunotherapy can be extremely effective in a small minority even of such 
patients (16). Active immunization protocols and treatment with immunomodulators such as anti-
CTLA-4 and anti-PD-1 antibodies have also yielded excellent clinical benefits, possibly even cures, in 
some patients. However, the fraction of patients responding favorably to any of these approaches has 
always been rather small. Furthermore, all patients participating in these trials are at high risk for 
severe or even fatal side effects (17-19). Biomarkers, or in our case immune parameters which can 
predict a beneficial course of disease for late-stage melanoma patients, regardless of the nature of 
their previous or current therapies, are therefore urgently needed. We previously reported that the 
presence of circulating NY-ESO-1- and/or Melan-A-reactive T cells predicted survival better than the 
AJCC M category and independent of therapy (15). In contrast to commonly-applied approaches to 
detect antigen-specific T cells, such as ELISPOT or multimer stainings, we developed a functional 
assay enabling collation of data on type of cells responding and type of response generated, 
independent of the HLA type of the patient. Here, we have taken this analysis further by asking 
whether knowledge of the nature of the responding T cell (CD4+ or CD8+) and the nature of the 
response (unopposed pro-inflammatory, anti-inflammatory or mixed pro- and anti-inflammatory; mono- 
or polyfunctional) would facilitate a finer analysis of the immunological parameters, and/or might even 
predict long-term survival. Furthermore, our approach has some important advantages compared to 
established techniques. ELISPOT and other cytokine capture assays usually detect only one cytokine, 
routinely IFN- γ. Based on our data, only about 70% (69% for NY-ESO-1 and 64% for Melan-A) of 
patients with antigen-specific T cells would be detected if the assay readout was restricted to this 
cytokine alone. We would therefore recommend the additional detection of at least one more cytokine 
(TNF or IL-2) to cover a broader range of specific T cells. Multimer assays, on the other hand, are 
mainly performed using MHC class I epitopes and detect therefore only CD8+, antigen-specific T cells 
(including anergic T cells). However, our results suggest that every antigen is preferentially detected 
by a certain cell type and that amongst antigen-specific T cells, the CD8+ fraction can be rather small. 
We found that when patients´ PBMC are challenged with peptides representing the entire NY-ESO-1 
molecule presented on a large number of different HLA alleles in multiple different patients, it is mainly 
a CD4+ T cell response that is triggered under these assay conditions. This may be important in the 
context of the many cancer immunotherapy trials exploiting NY-ESO-1 as a target antigen of choice in 
recent years. Approaches such as vaccination with predicted MHC class I epitopes aim to increase the 
number of CD8+ cytotoxic T cells which may not lead to as promising results as targeting CD4+ T cells 
could for the NY-ESO-1 antigen. Furthermore, monitoring projects using MHC-I-multimers, especially 
after systemic treatment like chemotherapy or application of cytokines, might be yield a distorted 
impression. CD8+ NY-ESO-1-reactive T cells may be underrepresented and unmeasured CD4+ 
responses (in our study 64% of all NY-ESO-1-specific T-cells) might be one of the reasons for the 
deficiency of data showing correlations between clinical outcome and immunological findings. For 
example, Jäger et al. found only 3 of 15 stage IV melanoma patients with detectable CD8+ NY-ESO-1-
specific T cells, using tetramer technology (NY-ESO-1 p157-165) (20). Valmori et al. were able to detect 
CD8+ NY-ESO-1-reactive T cells (using intracellular cytokine staining after in vitro stimulation) in only 
6 of 11 vaccinated melanoma patients, whereas CD4+ responses could be detected in all but one 
patient (21).     
Nevertheless, although stimulation with NY-ESO-1 led generally more often to CD4+ T cell responses, 
Kaplan-Meier analysis did not reveal an impact on individual patients’ survival time based on whether 
they mediated a CD4+ and/or CD8+ T-cell response against this antigen. The possession of either 
CD4+ or CD8+ T cells, or both, able to recognize the NY-ESO-1 antigen, seems equally associated 
with better survival. Robbins et al. showed that the adoptive transfer of genetically engineered, CD4+ 
and CD8+ T-cells reactive to NY-ESO-1 led to a regression of tumor mass in 5 of 11 melanoma 
patients (22). Yuan et al. observed that 6 of 8 Ipilimumab-treated patients with evidence of clinical 
benefit (partial response, complete response, stable disease) showed CD4+ and CD8+ T cell 
responses against 20-mer NY-ESO-1 overlapping peptides. Interestingly, none of these patients 
possessed a solely CD8+ response. Similar to our results, only 1 of 5 patients that progressed or died 
showed a response on NY-ESO-1 stimulation (23). Thus, the NY-ESO-1 antigen is a candidate target 
of choice for immunotherapy of malignant melanoma. Hunder et al. reported about durable clinical 
remissions, which were mediated by CD4+ T cell clones with specificity for NY-ESO-1, in an advanced 
melanoma patient (24). 
In contrast to NY-ESO-1, we found that the T cells responding to Melan-A were mainly CD8+. 
Strikingly, the CD4 or CD8 nature of the patient´s responding T cells had a strong impact on survival 
time. When CD4+ T cells responding to Melan-A were present, the probability of long-term survival 
was low, perhaps reflecting preferential activation of CD4+ regulatory T cells, consistent with the 
findings of their IL-10 production. Alternatively, the reactivity of CD4+ T cells in the absence of CD8+ 
T-cells might imply a humoral immune response against Melan-A in these patients, which may be 
associated with disease progression. However, the former explanation seems most likely, as only 3/9 
patients possessed Melan-A-reactive CD4+ T cells with a Th2-like cytokine profile, and because even 
when reactive CD8+ T cells were seen, the presence of reactive CD4+ T cells was still associated with 
poor survival. Klein et al. reported on a single advanced melanoma patient treated with Ipilimumab 
monotherapy. The patient showed increasing partial tumour remissions during therapy that finally 
resulted in a complete disappearance of all metastases. This was accompanied by a very large 
increase of CD8+ Melan-A-specific T cells (detected with tetramers; Melan-A26-35). Interestingly, CD8+ 
NY-ESO-1-specific T cells could not be detected (25). 
We also show here for the first time that the nature of the response observed in vitro, namely whether 
solely pro-inflammatory or also anti-inflammatory, had a great impact on the patients’ course of 
disease, at least for Melan-A. The stratification of patients with Melan-A-reactive T cells according to 
whether these cells mediated an unopposed pro-inflammatory response (only IFN-g and/or TNF 
and/or IL-2 and/IL-17) or whether there were also anti-inflammatory mediators involved (IL-4 and/or IL-
10) was informative in this regard. Patients with an unopposed pro-inflammatory response to Melan-A 
stimulation survived much longer than those with an anti-inflammatory response. Khammari et al. 
treated metastatic melanoma patients with Melan-A-Specific CTL clones (generated by in vitro 
stimulations with Melan-A peptide analog; ELAGIGILTV). Among 14 treated patients, six (43%) 
showed an objective response (complete and partial response), one patient had stable disease. It is 
reported that all selected clones were able to produce IL-2 upon stimulation with melanoma cell lines, 
but unfortunately, anti-inflammatory cytokines were not measured (26). This impact on survival could 
not be observed for patients with NYE-reactive T cells. However, consistent with our results, Ayyoub et 
al. observed that CD4+, NY-ESO-1-specific T cells (detected with MHC II/His-tag-peptide tetramers; 
DR52b/ESO123-137) produce mainly IFN- γ, TNF and IL-2 and only minor proportions of IL-4 and IL-17. 
IL-10 could not be detected (27). 
Both findings concerning Melan-A-reactivity may have important implications for the development of 
future immunotherapeutic protocols. Many clinical trials, especially using DNA, RNA or whole protein 
vaccination, lead to both Melan-A-specific CD4 and CD8 responses, which according to the results 
presented here, may be counterproductive. Additionally, the advantage of mediating a solely pro-
inflammatory response may imply that vaccination is unlikely to succeed. Hence, adoptive T-cell 
transfer with previously-generated, Melan-A-specific CD8+ cells preselected for mediating a solely 
pro-inflammatory response might be the most promising way of exploiting immune responses against 
this particular target antigen. Concerning NY-ESO-1-reactivity, we confirmed the important role of 
both, CD4+ and CD8+ mediated responses for tumour management and strengthened the role of NY-
ESO-1 as immunotherapeutic target. We believe that these types of analyses, even though they use 
peripheral blood and do not speak to what is actually happening inside the tumor, nonetheless reflect 
the latter events in an informative manner and at the very least allow patient stratification for selection 
of the most appropriate therapy. 
  
Figures/Tables: 
 
 
 
Figure 1: 
Type of T cell (white = CD4+ T cell; black = CD8+ T cell) responding upon antigen stimulation. If the 
patient had both CD4+ and CD8+ antigen-specific T-cells, the response was defined as mixed (grey) 
 
 
 
 
 
 
Figure 2: 
Proportion of patients with T cells releasing different cytokines by all patients with detectable T cells 
responding to NY-ESO-1 (A), Melan-A (B) or Influenza (C)  
 
 Figure 3: 
Detected cytokines by antigen-reactive T cells after restimulation with corresponding antigens. 
Responses were stratified into CD4 (white) and CD8 (black) driven responses.  
 
 
Figure 4: 
Proportion of single (blue) and multiple (red) cytokine responses upon antigen stimulation in patients 
with NY-ESO-1 (left) and Melan-A (right) reactive T cells.   
 
 
 Figure 4: 
Survival of stage IV melanoma patients with Melan-A-reactive T cells. Patients are grouped according 
to the absence CD4 (orange) or CD8 (green) responses or a mixed response (black) (A); or the 
absence of an anti- (blue) or pro-inflammatory (red) or combined (black) Melan-driven response 
respectively (B). Survival of patients without any detectable Melan-A-reactive T cells (Historical 
control) are plotted for comparison 
 
 
 
 
 
 
 
 
  
 
 
Table 1: 
Results of survival analysis according to Kaplan-Meier. Patients with NY-ESO-1- (upper part) or 
Melan-A-reactive T cells (lower part) were grouped according to phenotypical and functional 
characteristics. P values are results of Log-rank (Mantel-Cox) Test 
 
 
 
  
Antigen Factor No. % Dead MST [days] 1-Year Survival Rate P
NY-ESO-1 CD4 responses absent 3 100% 240 33,33%
CD8 responses absent 23 65% 650 60,29% 0,1444
Both responses present 10 30% n.d. 80,00%
Anti-inflammatory cytokines absent 28 64% 650 63,80%
Pro-inflammatory cytokines absent 0 - - - 0,7728
Both cytokines present 8 63% 747 62,50%
Single cytokine response 8 63% 596 75,00% 0,8681
Multiple cytokine response 28 64% 747 60,15%
Factor No. % Dead MST [days] 1-Year Survival Rate P
Antigen CD4 responses absent 13 69% 1111 76,92%
Melan-A CD8 responses absent 3 100% 112 0,00% 0,0170
Both responses present 6 50% 1968 50,00%
Anti-inflammatory cytokines absent 16 63% 1111 75,00%
Pro-inflammatory cytokines absent 3 67% 338 33,33% 0,0005
Both cytokines present 3 100% 54 0,00%
Single cytokine response 9 78% 824 66,67% 0,8642
Multiple cytokine response 13 62% 679 53,85%
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Zusammenfassung 
 
Das maligne Melanom, der bösartige Tumor der Melanozyten, ist einer der 
Krebsarten mit den weltweit am stärksten ansteigenden Neuerkrankungen. In frühen 
Stadien (Stadium I und II) stellt die chirurgische Entfernung des Tumors die 
wichtigste und erfolgreichste Therapieform dar. In fortgeschrittenen Stadien, welche 
beim Melanom verhältnismäßig früh erreicht werden, gelten die Chemo- und 
Strahlentherapie als wichtigste Behandlungsmethoden. Aufgrund der sehr geringen 
Heilungschancen sind diese Methoden jedoch eher als palliative Therapien 
anzusehen. Die geringe Aussicht auf Erfolg führte in den letzten Jahren vermehrt 
dazu, nach alternativen Therapieansätzen zu suchen und diese auch anzuwenden. 
Hierbei hat sich besonders die Krebsimmuntherapie als vielversprechend 
herausgestellt. Das Ziel solch einer Immuntherapie ist es, das Immunsystem des 
Patienten derart zu beeinflussen, dass sämtliche Krebszellen im Körper gezielt 
bekämpft und idealerweise beseitigt werden. Die Krebszellen sollen hierbei über 
Tumor-assoziierte Antigene (TAA), also Antigene die nur oder vermehrt auf 
Krebszellen vorkommen, erkannt werden. TAAs wurden zuerst und später besonders 
häufig auf Melanomzellen identifiziert. Die Antigene werden von unterschiedlichen 
Tumoren, unterschiedlich stark exprimiert und sind teilweise mit bestimmten 
klinischen Verläufen assoziiert. Die Entdeckung der TAAs auf Melanomzellen und 
der eindeutige Einfluss immunologischer Faktoren (Spontanremissionen, aggressive 
Verläufe bei Immunsupprimierten) führten dazu, dass die Immuntherapie schnell ein 
häufig eingesetztes Mittel zur Behandlung des malignen Melanoms wurde.  
Unterschiedliche immuntherapeutische Ansätze führten teilweise zu 
beeindruckenden Erfolgen, allerdings nur in wenigen Patienten. Außerdem setzen 
sich alle Teilnehmer an klinischen Studien, schweren und teilweise 
lebensbedrohlichen Nebenwirkungen aus. Das Ziel dieser Dissertation war es 
deshalb zum einen die Sicherheit und zum anderen vor allem klinische und 
immunologische Wirksamkeit einer intratumoralen IL-2 Behandlungen zu 
untersuchen. Des Weiteren sollten Antigene identifiziert werden, die als Ziel einer 
spezifischen Immuntherapie  zu besonders guten klinischen Ergebnissen  führen. 
Schließlich sollte analysiert werden, ob sich die Präsenz bestimmter antigen-
spezifischer T –Zellen als prädiktive Marker für einen guten Krankheitsverlauf eignen.  
Ich konnte zeigen, dass die intratumorale Injektion des Zytokins IL-2 eine sichere und 
effektive Behandlungsmethode, zumindest für sichtbare Läsionen ist. Außerdem 
wurde in einem Patienten, simultan zu den Komplettremissionen, ein Anstieg von 
antigen-spezifischen T-Zellen beobachtet. Weitere Folgestudien sollen nun zeigen, 
ob dieser Anstieg einerseits auch in anderen Patienten beobachtet werden kann und 
andererseits mit einem guten klinischen Verlauf assoziiert ist. 
Bezüglich Tumor-assoziierte Antigene konnte ich zeigen, dass T-Zellen die in der 
Lage sind die Antigene NY-ESO-1 und Melan-A zu erkennen, vermehrt in Patienten 
mit einem guten klinischen Verlauf detektiert werden können. Die Präsenz oder 
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Abwesenheit dieser Zellen erlaubte es außerdem, den klinischen Verlauf des 
einzelnen Patienten vorauszusagen, ungeachtet der angewendeten Therapie und 
der TNM Klassifizierung. Diese Fähigkeit konnte für die weiteren untersuchten 
Antigene nicht beobachtet werden. NY-ESO-1 und Melan-A scheinen sich deshalb 
hervorragend als Ziel einer Immuntherapie zu eignen. 
Schließlich wurden der Phänotyp und die Funktion der einzelnen Antigen-
spezifischen Zelle untersucht. Ich konnte zeigen dass jedes der getesteten TAAs 
hauptsächlich von einem bestimmten T-Zelltyp (CD4+ oder CD8+) erkannt wird und 
zu einer bestimmten T-Zell-Antwort, also der Freisetzung von bestimmten Zytokinen, 
führt. Hierbei war auffallend, dass bezüglich der Melan-A-Reaktivität, es für den 
Patienten essentiell war, welcher Zelltyp und welche Immunantwort involviert waren. 
Die Abwesenheit von CD8+ T Zellen und die Präsenz von anti-inflammatorischen 
Zytokinen war jeweils mit einem sehr schlechten klinischen Verlauf assoziiert. 
Immuntherapeutische Ansätze, die den falschen Zelltyp beeinflussen oder zu einer 
falschen Zytokinantwort führen, könnten vermutlich nicht zu klinischen Erfolgen 
führen. Ob die Immuntherapie des malignen Melanoms unter Berücksichtigung der 
Ergebnisse dieser Arbeit jedoch erfolgreicher wird, bleibt abzuwarten.   
  
